http://www.alloftv.com/rss/feeds/news/media-releases.xml en Novartis maintains strong operational performance in Q1, confirms FY 2020 guidance at this time, and advances a broad range of efforts to support the global response to COVID-19 http://www.alloftv.com/news/media-releases/novartis-maintains-strong-operational-performance-q1-confirms-fy-2020-guidance <ul><li><strong>Q1 2020 net sales from continuing operations<sup>1</sup> grew 13% (cc<sup>2</sup>, +11% USD) with double digit growth (cc) in Innovative Medicines and Sandoz:</strong><ul><li>Key growth drivers include <em>Entresto</em> USD 569 million (+62% cc), <em>Zolgensma</em> USD 170 million, <em>Cosentyx</em> USD 930 million (+19% cc), <em>Kisqali</em> USD 161 million (+82% cc) and <em>Piqray </em>USD 74 million</li><li>Biopharmaceuticals grew 31% (cc) to USD 450 million, with strong growth in Europe</li><li>Excluding COVID-19 related forward purchases, we estimate<sup>3</sup> sales ...</li></ul></li></ul> Apr 28, 2020 22126 Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients http://www.alloftv.com/news/media-releases/novartis-sponsor-large-clinical-trial-hydroxychloroquine-hospitalized-covid-19 <ul><li><em>Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease </em><p>?</p></li><li><em>Trial is designed and implemented quickly to address the need for science-based investigation following early preclinical and clinical evidence<sup>1,2,3</sup> that hydroxychloroquine may help hospitalized patients with COVID-19 disease? </em><br />?</li><li><em>Company will also make its hydroxychloroquine intellectual property available to support broad access if ...</em></li></ul> Apr 20, 2020 22121 Novartis announces mutual agreement to terminate sale of Sandoz US generic oral solids, dermatology portfolio to Aurobindo http://www.alloftv.com/news/media-releases/novartis-announces-mutual-agreement-terminate-sale-sandoz-us-generic-oral-solids <p><b>Basel, April 1, 2020</b> – Novartis today announced the mutual agreement with Aurobindo Pharma USA Inc. to terminate the agreement to sell the Sandoz US generic oral solids and dermatology businesses to Aurobindo Pharma USA Inc. This decision was taken as approval from the U.S. Federal Trade Commission for the transaction was not obtained within anticipated timelines.</p><p>?</p><p>Sandoz will continue to operate its oral solids and dermatology business as part of the Sandoz US business. </p><p>?</p><p>?</p><p class="Subhead">Disclaimer</p><p>This press release contains forward-looking ...</p> Apr 02, 2020 22101 Novartis donation: Consignment of 30 million hydroxychloroquine tablets ships to US Department of Health and Human Services http://www.alloftv.com/news/media-releases/novartis-donation-consignment-30-million-hydroxychloroquine-tablets-ships-us <p><b>Princeton</b> - Novartis announced today that Sandoz, its generics and biosimilars division, has started to ship a consignment of 30 million doses of hydroxychloroquine tablets to the US Department of Health and Human Services (HHS) for immediate use in controlled clinical studies. The study will evaluate the medicine’s effectiveness in people who have tested positive for COVID-19. The shipment is part of the previously announced global Novartis donation of 130 million tablets in total to be distributed across a variety of clinical trials and stakeholders internationally. </p><p>?</p> ... Mar 30, 2020 22091 Sandoz announces new country head for Japan http://www.alloftv.com/news/media-releases/sandoz-announces-new-country-head-japan <ul><li><i>Shingo Iwamoto appointed country head for Sandoz in Japan</i></li><li><i>Shingo Iwamoto will also oversee Japanese business of Aspen Global Incorporated (AGI), successfully acquired by Sandoz on February 1 this year </i></li><li><i>Japan, world’s third largest generics and off-patent market, is central to Sandoz global strategy</i></li></ul><p><b>Tokyo, March 25, 2020</b> <b>– </b>Sandoz announced today that Shingo Iwamoto, currently President and representative director of Aspen Japan, has been appointed Country Head for Sandoz in Japan with effect from April 1, 2020. He will ...</p> Mar 25, 2020 22086 Novartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response http://www.alloftv.com/news/media-releases/novartis-commits-donate-130-million-doses-hydroxychloroquine-support-global <ul><li><em>Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19.</em></li><li><em>Novartis Sandoz division will pursue appropriate regulatory authorizations and, upon approval, will work with stakeholders to determine how best to get this medicine to the patients who need it</em></li><li><em>Commitment builds on recently announced USD 20 million Novartis COVID-19 Response Fund, drug discovery and development collaborations and essential medicines price stability</em></li><li><em>Novartis encourages industry, ...</em></li></ul> Mar 20, 2020 22081 Sandoz Resolves Generic Drug Antitrust Investigation in the U.S. http://www.alloftv.com/news/media-releases/sandoz-resolves-generic-drug-antitrust-investigation-us <p>Department of Justice (DOJ) Antitrust Division concerning the Department’s more than three-year-long antitrust investigation into the U.S. generic drug industry. The Sandoz resolution relates to instances of misconduct at the company between 2013 and 2015 with regard to certain generic drugs sold in the United States. As part of the resolution, Sandoz has agreed to pay USD 195 million and will enter into a deferred prosecution agreement (DPA). </p><p>Sandoz is a global leader in generic pharmaceuticals and biosimilars with a broad portfolio of high-quality medicines covering all major ...</p> Mar 02, 2020 22041 Sandoz commits to keep prices stable for basket of essential COVID-19 medicines; Novartis responds to COVID-19 with broad range of initiatives http://www.alloftv.com/news/media-releases/sandoz-commits-keep-prices-stable-basket-essential-medicines <p>Sandoz, a global generics leader and the #1 provider of off-patent antibiotic medicines worldwide, is making a public commitment to ensure stable pricing for a basket of essential medicines the company markets, which may help to treat coronavirus patients, amid growing concerns about the potential impact of the coronavirus outbreak on global supply chains.</p><p>Richard Saynor, Sandoz CEO, says: “I am very concerned about reports that prices for basic medicines such as painkillers and antibiotics are rising substantially as a result of a tightening supply situation for active ...</p> Feb 26, 2020 22031 Sandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world’s third largest market for generics and off-patent medicines http://www.alloftv.com/news/media-releases/sandoz-completes-acquisition-aspen%27s-japanese-operations-strengthening-its <ul><li><em>Successful acquisition of Aspen’s Japanese operations and assets reinforces strategic focus on Japan, world’s third largest market for generics and off-patent medicines</em></li><li><em>Acquired portfolio complements existing Sandoz portfolio and consists primarily of off-patent branded medicines with focus on anaesthetics and specialty brands</em></li><li><em>Transaction enables </em><em>Sandoz to increase portfolio and pipeline offerings in hospital setting, expanding number of patients who can gain access to these important medicines</em>??</li></ul><p><strong>Holzkirchen, ...</strong></p> Jan 31, 2020 22021 Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019 http://www.alloftv.com/news/media-releases/novartis-delivered-strong-sales-growth-margin-expansion-and-breakthrough <ul><li><strong>Full year net sales for c</strong><strong>ontinuing operations<sup>1</sup></strong><strong> up 9% (cc<sup>2</sup>, +6% USD):</strong><ul><li>Pharmaceuticals BU growing 12% (cc) driven by <em>Cosentyx</em> USD 3.6 billion (+28% cc), <em>Entresto</em> USD 1.7 billion (+71% cc) and <em>Zolgensma</em> USD 361 million </li><li>Oncology BU growing 10% (cc) driven by <em>Promacta/Revolade </em>USD 1.4 billion (+23% cc), <em>Kisqali </em>USD 0.5 billion (+111% cc) and <em>Lutathera</em> USD 0.4 billion (+160% cc)</li><li>Sandoz sales grew 2% (cc, -1% USD) driven by Biopharmaceuticals ...</li></ul></li></ul> Jan 29, 2020 22011 Sandoz officially recognized as Global Top Employer 2020 http://www.alloftv.com/news/media-releases/sandoz-officially-recognized-global-top-employer-2020 <ul><li>Sandoz officially recognized by Top Employers Institute for its exceptional employee offerings globally</li><li>People-first policies such as global equal parental leave for 14 weeks and joining the Equal Pay International Coalition contributed to recognition</li><li>Second such annual certification for Sandoz, underlining ongoing commitment to attract and keep best talent by building a great place to work</li></ul><p><strong>Holzkirchen, January 30, 2020 </strong>– Sandoz, a Novartis division, is pleased to announce that it has been officially awarded the “Global Top Employer 2020” ...</p> Jan 30, 2020 22006 Sandoz presents real-world data showing effectiveness of Erelzi? (etanercept-szzs) in rheumatic disease treatment http://www.alloftv.com/news/media-releases/sandoz-presents-real-world-data-showing-effectiveness-erelzi-etanercept-szzs <ul type="disc"><li><em>Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/ARP Annual Meeting </em></li><li><em>US analysis of long-term financial impact when switching to biosimilar etanercept also presented, modeling significant cost savings for health systems </em></li><li><em>Sandoz is the pioneer and a global leader in biosimilars, with eight approved biosimilars worldwide and more than 10 in the pipeline</em></li></ul><p><strong>Holzkirchen, November 12, 2019</strong> – Sandoz, a Novartis division and a global ...</p> Nov 12, 2019 21981 Sandoz announces agreement to acquire Aspen’s Japanese operations and associated assets, strengthening position in world’s third largest generics market http://www.alloftv.com/news/media-releases/sandoz-announces-agreement-acquire-aspen%27s-japanese-operations-and-associated <ul><li><em>Planned acquisition reinforces Sandoz strategic focus on Japan</em></li><li><em>Aspen portfolio in Japan consists primarily of off-patent branded medicines with focus on anesthetics and specialty brands</em></li><li><em>Medicines complement Sandoz broad hospital portfolio and pipeline in Japan thereby expanding access to the hospital channel </em></li></ul><p><strong>Holzkirchen, Germany</strong><strong>, November 11, 2019 – </strong>Sandoz today announced that it has entered into a binding agreement for the planned acquisition of the Japanese business of Aspen Global Incorporated ...</p> Nov 11, 2019 21976 Novartis delivered another strong quarter with double digit sales growth and core1 margin expansion; 2019 sales and profit guidance raised; Beovu launched in US http://www.alloftv.com/news/media-releases/novartis-delivered-another-strong-quarter-double-digit-sales-growth-and-core1 <ul type="disc"><li><strong>Continuing operations<sup>2</sup></strong><strong> net sales up 13% (cc<sup>1</sup>, +10% USD) driven by:</strong><br /><ul type="circle"><li>Cosentyx sales of USD 937 million (+27% cc), with strong demand across indications and regions</li><li>Entresto USD 430 million (+61% cc), with increased demand in hospital and ambulatory settings</li><li>Zolgensma sales of USD 160 million, strong launch including broad access</li><li>Lutathera sales grew to USD 119 million, total AAA sales were USD 177 million</li><li>Piqray sales were USD 43 million, off to a strong start ...</li></ul></li></ul> Oct 22, 2019 21971 Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine http://www.alloftv.com/news/media-releases/sandoz-announces-global-deal-commercialize-proposed-biosimilar-natalizumab-key <ul type="disc"><li><em>Worldwide agreement with Polpharma?Biologics gives Sandoz commercialization rights to proposed biosimilar natalizumab for relapsing-remitting multiple sclerosis (RRMS) </em></li><li><em>RRMS affects ~85% of MS patients and can create a substantial social and economic burden on patients, their families and healthcare systems[1],[2] </em></li><li><em>Natalizumab is fifth proposed biosimilar in-licensed by Sandoz in nine months, underscoring commitment to further grow pipeline through collaborations</em></li></ul><p><strong>Holzkirchen, Germany, September 3, 2019 ...</strong></p> Sep 03, 2019 21966 Sandoz receives US FDA approval for long-acting oncology supportive care biosimilar ZiextenzoTM (pegfilgrastim-bmez) http://www.alloftv.com/news/media-releases/sandoz-receives-us-fda-approval-long-acting-oncology-supportive-care-biosimilar <ul type="disc"><li><em>Ziextenzo??is indicated to decrease the incidence of febrile neutropenia, one of the most serious side effects of chemotherapy</em><br /><em>?</em></li><li><em>With approval of Ziextenzo??, Sandoz is first and only company to offer US physicians long- and short-acting filgrastim biosimilar treatment options</em><br />?</li><li><em>With four US approved biosimilars, Sandoz is committed to expanding patient access, increasing healthcare savings and fueling innovation </em></li></ul><p><strong>Holzkirchen, Nov. 5, 2019</strong> – Sandoz, a Novartis division and a global ...</p> Nov 05, 2019 21956 Sandoz will appeal District Court of New Jersey ruling in biosimilar Erelzi? (etanercept-szzs) US patent case http://www.alloftv.com/news/media-releases/sandoz-will-appeal-district-court-new-jersey-ruling-biosimilar-erelzi-etanercept <ul type="disc"><li><em>Sandoz to appeal court ruling to United States Court of Appeals for the Federal Circuit</em></li><li><em>Ruling prevents launch of important, affordable treatment option for US patients affected by chronic autoimmune and inflammatory diseases </em></li><li><em>Sandoz remains deeply committed to providing Erelzi<sup>?</sup> as soon as possible, contributing to a more sustainable healthcare system</em></li></ul><p><strong>Holzkirchen, Germany, 9 August 2019</strong> – Sandoz, a Novartis division and a global leader in biosimilars, today announced that the United States ...</p> Aug 09, 2019 21951 Sandoz announces first patient enrolled in clinical study for proposed biosimilar denosumab in osteoporosis http://www.alloftv.com/news/media-releases/sandoz-announces-first-patient-enrolled-clinical-study-proposed-biosimilar <ul type="disc"><li><i>Integrated Phase I/lll study for proposed biosimilar denosumab to confirm matching efficacy, safety and immunogenicity with reference medicine[1]? </i></li><li><i>Osteoporosis accounts for 8.9m bone fractures annually, including debilitating hip fractures -- number set to increase substantially over next two decades[2]</i></li><li><i>Sandoz has eight marketed biosimilar medicines globally and 10+ molecules in the pipeline including proposed biosimilar denosumab </i></li></ul><p><b>Holzkirchen, July 22, 2019 </b>- Sandoz, a Novartis division and a global leader in ...</p> Jul 22, 2019 21946 Novartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased http://www.alloftv.com/news/media-releases/novartis-delivers-strong-sales-double-digit-core-operating-income-growth-and <ul type="disc"><li><b>Continuing operations[1] net sales up 8% (cc[2], +4% USD) driven by:</b><br /><ul type="circle"><li><i>Cosentyx</i> at USD 858 million, +25% (cc) mainly driven by continued strong US growth (+31%)</li><li><i>Entresto</i> grew to USD 421 million, +81% (cc) with increased initiation in hospital and ambulatory settings</li><li>Oncology sales grew 9% (cc) driven by growth from <i>Lutathera</i> (USD 109 million), <i>Kisqali</i> (USD 111 million) and <i>Kymriah</i> (USD 58 million) in the second quarter</li><li>Sandoz sales grew 3% (cc, -1% USD) as ex-US growth more than ...</li></ul></li></ul> Jul 18, 2019 21936 Sandoz extends SYMJEPI? (epinephrine) Injection launch to US pharmacies to help improve patient access to life-saving medicine http://www.alloftv.com/news/media-releases/sandoz-extends-symjepi-epinephrine-injection-launch-us-pharmacies-help-improve <ul><li><i>Adult and pediatric </i><i>doses immediately available as single-dose, pre-filled syringe and device combination for emergency treatment of Type 1 allergic reactions, including anaphylaxis<sup>1</sup></i></li></ul><ul><li><i>SYMJEPI will help address critical impact of ongoing epinephrine auto-injector shortages<sup>2</sup> for the one in 50 Americans at risk for anaphylaxis<sup>3</sup></i></li></ul><ul><li><i>Sandoz is committed to helping people access high quality healthcare at affordable prices, with strong focus on areas of unmet patient need</i></li></ul><p><b>Princeton, New ...</b></p> Jul 09, 2019 21931 Sandoz launches oncology generic gefitinib in 13 EU countries at loss of market exclusivity, expanding access to essential medicine http://www.alloftv.com/news/media-releases/sandoz-launches-oncology-generic-gefitinib-13-eu-countries-loss-market <ul type="disc"><li><i>Sandoz gefitinib indicated for adult patients with locally advanced or metastatic non-small cell lung cancer[1] with activating mutations of EGFR-TK[1]</i></li><li><i>More than 300,000 European men and women are diagnosed with lung cancer annually, making it the fourth most common cancer[2]</i></li><li><i>With launch Sandoz builds on robust 50+ medicine oncology portfolio globally, including chemotherapy, targeted therapy, hormones and supportive care[3]</i></li></ul><p><b>Holzkirchen, Germany, July 2, 2019</b> <b>- </b>Sandoz today announced the launch of the generic ...</p> Jul 02, 2019 21911 Sandoz enters agreement with Kit Check to track, automate restocking of products in U.S. hospitals http://www.alloftv.com/news/media-releases/sandoz-enters-agreement-kit-check-track-automate-restocking-products-us <ul><li><i>Sandoz and Kit Check will help hospital pharmacies cut costs, reduce risk, and better support hospital staff in treating their patients safely and more efficiently </i></li></ul><ul><li><i>Collaboration will optimize supply chain by providing real-time inventory reports, plus timely tracking of recalls and expiration of products</i></li></ul><ul><li><i>Kit Check? uses powerful machine learning and advanced tracking technology to streamline medication inventory, workflow, and auditing processes</i></li></ul><p><b>Princeton, New Jersey</b>, June 27, 2019 – Sandoz Inc, a Novartis ...</p> Jun 27, 2019 21906 New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy http://www.alloftv.com/news/media-releases/new-sandoz-biosimilar-adalimumab-data-confirms-switching-reference-biologic-has <div class="panel-pane pane-entity-field pane-node-body"><div class="pane-wrapper"><div class="pane-content"><div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><ul type="disc"><li><i>Data show switching to Hyrimoz<sup>?</sup> (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis[1]</i><br />?</li><li><i>ADMYRA data reinforces review summarizing 90+ publications, that switching from reference ...</i></li></ul></div></div></div></div></div></div> Jun 14, 2019 21901 Sandoz announces plan to improve competitiveness and realign the organization, to drive ongoing Transformation and support future growth http://www.alloftv.com/news/media-releases/sandoz-announces-plan-improve-competitiveness-and-realign-organization-drive <ul><li><i>Two-stage strategic Transformation plan foresees measures for organizational realignment, followed by increased investments to drive growth segments</i></li><li><i>Realignment of organization involves a planned reduction of global workforce by approximately 900 FTEs, including closure of Holzkirchen development center</i></li></ul><p><b>HOLZKIRCHEN, May 15, 2019</b> – Sandoz today announces plans for a leaner and more efficient global organization, to drive cost competitiveness as the first stage of its ongoing strategic Transformation and support investments into future growth. ...</p> May 15, 2019 21896 Sandoz demonstrates strategic focus on China, with first-of-a-kind generic approval under Quality Consistency Evaluation system http://www.alloftv.com/news/media-releases/sandoz-demonstrates-strategic-focus-china-first-kind-generic-approval-under <ul type="disc"><li><i>Sandoz receives generic approval for Rosuvastatin from China's National Medical Products Administration (NMPA) under Quality Consistency Evaluation (QCE) system </i></li><li><i>Generic approval under China's recently introduced QCE system is first of a kind for multinational pharmaceutical company</i></li><li><i>Regulatory milestone demonstrates long-term strategic focus on pioneering access to high-quality medicines in world's largest, and rapidly-growing, generics market</i></li></ul><p><b>Holzkirchen, Germany</b><b>, May 9, 2019 - </b>Sandoz today announced that it ...</p> May 09, 2019 21886 Sandoz enters agreement for proposed trastuzumab biosimilar, currently in Phase III development, to treat selected HER2-positive cancer tumors http://www.alloftv.com/news/media-releases/sandoz-enters-agreement-proposed-trastuzumab-biosimilar-currently-phase-iii <ul type="disc"><li><i>Collaboration covers proposed trastuzumab biosimilar in Phase III development for human epidermal growth factor receptor 2 positive (HER2+) breast and gastric tumors</i></li><li><i>Per licence agreement, EirGenix, Inc is responsible for development and manufacturing; Sandoz has right to commercialize in all markets except China and Taiwan</i></li><li><i>Agreement is third announced biosimilars collaboration for Sandoz in 18 months; will build on robust portfolio of eight approved molecules, with a further 10-plus in development</i></li></ul><p><b>Holzkirchen, Germany, ...</b></p> Apr 30, 2019 21881 Novartis starts 2019 with strong sales and double digit core[1] operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgraded http://www.alloftv.com/news/media-releases/novartis-starts-2019-strong-sales-and-double-digit-core1-operating-income-growth <ul type="disc"><li><b>Transformation to focused medicines company continued with the spin-off of Alcon; </b>commentary below is on continuing operations[2]</li><li><b>Continuing operations</b><b> net sales up 7% (cc[1], +2% USD) driven by Innovative Medicines:</b><br /><ul type="circle"><li>Cosentyx was USD 791 million, +41% (cc) with strong demand growth in all indications and regions</li><li>Entresto grew to USD 357 million, +85% (cc) including the benefit from new data on hospital initiation</li><li>Oncology sales grew 9% (cc) mainly driven by Lutathera (USD 106 million), Promacta (USD ...</li></ul></li></ul> Apr 24, 2019 21876 Sandoz drives differentiated portfolio with deal to commercialize new treatment for Opioid-Induced Constipation in key European countries http://www.alloftv.com/news/media-releases/sandoz-drives-differentiated-portfolio-deal-commercialize-new-treatment-opioid <ul type="disc"><li><i>Agreement with Shionogi to commercialize Rizmoic? (naldemedine) in Germany, UK and Netherlands, plus right of first refusal for certain other European markets</i></li><li><i>Rizmoic<sup>? </sup>is an innovative medicine for treating constipation caused by opioid pain relief medicines, in patients who have previously been treated with a laxative</i></li><li><i>Agreement reinforces Sandoz anti-pain franchise and commitment to pioneer access to healthcare in areas of unmet medical need</i></li></ul><p><b>HOLZKIRCHEN, April 11 2019 </b>- Sandoz today announces that it has ...</p> Apr 11, 2019 21871 Sandoz resubmits biosimilar pegfilgrastim application to US FDA http://www.alloftv.com/news/media-releases/sandoz-resubmits-biosimilar-pegfilgrastim-application-us-fda <ul type="disc"><li><i>Sandoz pursues US approval for biosimilar pegfilgrastim, a long-acting version of supportive oncology medicine filgrastim</i><br />?</li><li><i>Pegfilgrastim is used to reduce the incidence of neutropenia, one of the most serious side effects of chemotherapy, hospitalizing 60,000 US cancer patients each year<sup>1</sup></i><br />?</li><li><i>Sandoz is committed to </i><i>fostering biosimilar competition, to offer high-quality, cost-effective medicines and contribute to a more sustainable healthcare system</i></li></ul><p><b>Holzkirchen, </b><b>April 3, 2019</b> <b>- ...</b></p> Apr 02, 2019 21866 Novartis announces change in Sandoz leadership http://www.alloftv.com/news/media-releases/novartis-announces-change-sandoz-leadership <ul type="disc"><li><i>Richard Francis, CEO Sandoz, to step down on March 31, 2019</i></li><li><i>Francesco Balestrieri, Head Region Europe, Sandoz, appointed ad-interim CEO Sandoz </i></li></ul><p><b>Basel, March 14, 2019 </b>- Novartis announced today that Richard Francis will be stepping down as CEO of Sandoz, a Novartis division, and as a member of the Executive Committee of Novartis on March 31, 2019. Francesco Balestrieri, currently Region Head Europe, Sandoz, has been appointed ad-interim CEO Sandoz. He will report to Vas Narasimhan, CEO, Novartis.</p><p>Vas Narasimhan said; "I would ...</p> Mar 14, 2019 21861 Three winners of 2019 Sandoz Healthcare Access Challenge (HACk) are announced at SXSW http://www.alloftv.com/news/media-releases/three-winners-2019-sandoz-healthcare-access-challenge-hack-are-announced-sxsw <ul type="disc"><li><i>Sandoz commits to increasing support from one winner to three, following impressive pitches from the finalists</i></li><li><i>Winning ideas proposed innovative uses of artificial intelligence, mobile apps and digital therapeutics to address healthcare access challenges</i></li><li><i>Sandoz invited people worldwide to "reimagine access to healthcare" by identifying practical, scalable digital solutions to address unmet medical needs </i></li></ul><p><b>Austin, Texas, March 10, 2019 <i>-</i> </b>Sandoz, a Novartis division, today announced the winners of the 2019 Sandoz ...</p> Mar 10, 2019 21856 Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018 http://www.alloftv.com/news/media-releases/novartis-delivered-strong-sales-growth-core-margin-expansion-built-leading <ul type="disc"><li><b>Full year net sales up 5% (cc[1], +6% USD) driven by strong performance of growth drivers:</b><br /><ul type="circle"><li>Pharmaceuticals BU grew 7% (cc) driven by Cosentyx USD 2.8 billion (+36% cc) and Entresto USD 1.0 billion (+102% cc)</li><li>Oncology BU grew 9% (cc) driven by AAA[2] (USD 0.4 billion) including Lutathera, Promacta/Revolade USD 1.2 billion (+35% cc) and Tafinlar + Mekinist USD 1.2 billion (+31% cc)</li></ul></li><li><b>Full year core[1] operating income grew 8% mainly driven by higher sales and gross margin expansion</b></li><li><b>Net income was USD ...</b></li></ul> Jan 30, 2019 21846 Sandoz certified Global Top Employer 2019 http://www.alloftv.com/news/media-releases/sandoz-certified-global-top-employer-2019 <ul><li><em>Sandoz has been officially certified by the Top Employers Institute for its exceptional employee offerings globally</em></li><li><em>The Top Employers Institute is generally acknowledged as the global authority on recognizing excellence in people practices</em></li><li><em>This exclusive certification underlines our commitment to build a great place to work, based on a strong purpose-driven strategy</em></li></ul><p><strong>Holzkirchen, January 31, 2019 </strong>– Sandoz, a Novartis division, is honored to announce that it has been officially certified “Global Top Employer 2019” ...</p> Jan 31, 2019 21841 Sandoz Inc. launches SYMJEPI? (epinephrine) in the US http://www.alloftv.com/news/media-releases/sandoz-inc-launches-symjepi-epinephrine-us <p><b>Princeton, New Jersey, January 16, 2019 </b>– Sandoz Inc. (Sandoz), a Novartis division, today announced the US market introduction of SYMJEPI? (epinephrine) 0.3 mg Injection for the emergency treatment of allergic reactions (Type 1), including anaphylaxis. Sandoz is launching this medicine as an affordable, single-dose, pre-filled syringe alternative to epinephrine auto-injectors.</p><p>SYMJEPI will be rolled out through a phased launch, first in the institutional setting – an established channel where Sandoz Inc. has significant experience and knowledge – followed by introduction into ...</p> Jan 16, 2019 21836 Sandoz selects three finalists for Healthcare Access Challenge (Sandoz HACk) from over 400 global entries http://www.alloftv.com/news/media-releases/sandoz-selects-three-finalists-healthcare-access-challenge-sandoz-hack-over-400 <ul><li><em>Competition generated ideas from more than 400 entrants in 80 countries – three shortlisted entrants from Uganda, the US and the Netherlands</em></li><li><em>Three finalists shared innovative uses of artificial intelligence, mobile apps and digital therapeutics to address local healthcare access challenges</em></li><li><em>Finalists will participate in a four-day “accelerator event” in March, collaborating with Sandoz to further refine their ideas, immediately ahead of final judging</em></li></ul><p><strong>Holzkirchen, January 16, 2019 </strong>– Sandoz, a Novartis division, ...</p> Jan 16, 2019 21831 Sandoz and Pear Therapeutics Announce US Launch of reSET-OTM to Help Treat Opioid Use Disorder http://www.alloftv.com/news/media-releases/sandoz-and-pear-therapeutics-announce-us-launch-reset-otm-help-treat-opioid-use <ul type="disc"><li>reSET-O(TM)* is the first US FDA-cleared prescription digital therapeutic for patients with Opioid Use Disorder</li><li>Cleared by the FDA in December, reSET-O is available immediately</li><li>As part of a broader focus on digital healthcare solutions at Novartis, Sandoz aims to increase patient engagement and improve access to treatment through digital solutions</li></ul><p><b>HOLZKIRCHEN, January 7, 2018 </b>- Sandoz Inc., a Novartis division, and Pear Therapeutics, Inc., announced today the US commercial launch of reSET-O(TM) for patients with Opioid Use Disorder (OUD ...</p> Jan 07, 2019 21826 Sandoz enters into commercialization and supply agreement for insulin biosimilars, anticipating growing demand as diabetes burden rises http://www.alloftv.com/news/media-releases/sandoz-enters-commercialization-and-supply-agreement-insulin-biosimilars <ul type="disc"><li><i>Agreement covers biosimilar insulins in early and clinical development for the top three selling branded insulins by sales: glargine, lispro and aspart </i></li><li><i>Over 400 million people worldwide have diabetes and the amount of insulin required to treat type 2 diabetes alone is expected to increase by more than 20% from 2018 to 2030</i><em>[1],[2]</em></li><li><i>Sandoz continues to strategically expand their biosimilars portfolio, with eight marketed biosimilars and a robust pipeline, showing ongoing commitment to accessible innovation</i></li></ul><p><b> ...</b></p> Dec 19, 2018 21821 Sandoz teams up to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR) http://www.alloftv.com/news/media-releases/sandoz-teams-drive-cutting-edge-digital-solutions-global-fight-against <ul><li><em>Strategic collaboration agreement with Curetis subsidiary Ares Genetics to develop digital platform for development and life-cycle management of antibiotics</em></li><li><em>Program will combine established microbiology laboratory techniques with advanced bioinformatics and AI methods</em></li><li><em>Short-term focus on repurposing existing antibiotics to treat infections involving multi-drug-resistant pathogens</em></li></ul><p><b>Holzkirchen, December 18, 2018</b> <b>– </b>Sandoz today announces the signature of a strategic collaboration agreement with Ares Genetics GmbH, to ...</p> Dec 18, 2018 21816 Sandoz Inc. and Pear Therapeutics Obtain FDA Clearance for reSET-O(TM) to Treat Opioid Use Disorder http://www.alloftv.com/news/media-releases/sandoz-inc-and-pear-therapeutics-obtain-fda-clearance-reset-otm-treat-opioid-use <ul type="disc"><li><i>reSET-O<sup>TM</sup> is the first FDA-cleared Prescription Digital Therapeutic (PDT) for patients with Opioid Use Disorder </i></li><li><i>Pear Therapeutics is leading the development of a new therapeutic class with two FDA-authorized PDTs and a robust pipeline of therapeutics across disease areas </i></li><li><i>Sandoz will lead U.S. commercial launch, anticipated in coming days in Q4</i></li><li><i>As part of broader Novartis digital revolution, Sandoz aims to increase patient engagement and improve access to treatment through digital solutions</i></li></ul><p><b> ...</b></p> Dec 10, 2018 21811 Sandoz certified Top Employer Asia Pacific 2019 http://www.alloftv.com/news/media-releases/sandoz-certified-top-employer-asia-pacific-2019 <ul><li><em>Sandoz has been certified by the Top Employers Institute for its exceptional employee offerings in Asia Pacific (APAC)</em></li><li><em>The annual, international research undertaken by the Top Employers Institute recognizes leading employers around the world</em></li><li><em>This exclusive certification underlines Sandoz′ commitment to build a great place to work</em></li></ul><p>Holzkirchen, December 4, 2018 – Sandoz, a Novartis division, has been certified “TOP Employer Asia Pacific 2019” for its exceptional employee offerings in the region. Sandoz is certified in five Asia ...</p> Dec 04, 2018 21796 Sandoz receives eighth European Commission approval for a biosimilar with Ziextenzo? (pegfilgrastim) http://www.alloftv.com/news/media-releases/sandoz-receives-eighth-european-commission-approval-biosimilar-ziextenzo <ul><li><i>Biosimilar Ziextenzo<sup>? </sup>(pegfilgrastim), a long-acting version of supportive oncology medicine filgrastim, is now approved for use in all reference medicine indications </i>[1]</li><li><i>Ziextenzo is indicated to reduce duration of neutropenia / incidence of febrile neutropenia, some of the most serious side effects of chemotherapy </i>[2]</li><li><i>Sandoz demonstrates commitment to making access happen for patients with eight biosimilars approved in EU, including five in last 18 months </i></li></ul><p><b>Holzkirchen, November 27, 2018</b> - Sandoz, a Novartis division ...</p> Nov 27, 2018 21716 Sandoz and Pear Therapeutics announce launch of reSET? for treatment of patients with Substance Use Disorder http://www.alloftv.com/news/media-releases/sandoz-and-pear-therapeutics-announce-launch-reset-treatment-patients-substance <ul><li><i>reSET</i><sup>?</sup><i> is the first and only FDA-authorized prescription digital therapeutic for Substance Use Disorder (SUD)</i></li><li><i>Adding reSET to outpatient therapy significantly improved abstinence in substances of abuse and treatment retention compared to standard of care alone</i></li><li><i>Sandoz and Novartis continue to embrace digital technologies to enhance R&amp;D and deliver better outcomes for patients</i></li></ul><p><b>Holzkirchen, </b><b>November 19, 2018 - </b>Sandoz, a Novartis division, and Pear Therapeutics, Inc., announced today the commercial launch ...</p> Nov 20, 2018 21711 Sandoz commits to practical and scalable solutions to combat growing global threat of antimicrobial resistance (AMR) http://www.alloftv.com/news/media-releases/sandoz-commits-practical-and-scalable-solutions-combat-growing-global-threat <ul><li><em>Antibiotics are the cornerstone of modern medicine, but AMR represents an increasingly serious threat to global public health<sup>1</sup></em></li><li><em>Sandoz, as the world’s leading provider of high-quality antibiotics, is committed to playing a key role in efforts to balance improved access and responsible use<sup>2</sup></em></li><li><em>Focus is on driving practical, scalable on-the-ground solutions across four key areas, to help make a true impact and contribute to agreed global goals<sup>3</sup></em></li></ul><p><strong>Holzkirchen, November 7, 2018</strong> <strong>– ...</strong></p> Nov 07, 2018 21696 Sandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needs http://www.alloftv.com/news/media-releases/sandoz-decides-not-pursue-us-biosimilar-rituximab-will-focus-robust-biosimilar <ul><li><i>Decision follows FDA request for additional information to complement submission for biosimilar rituximab</i></li><li><i>Sandoz stands behind safety, efficacy and quality of our biosimilar rituximab, which is already approved in EU, Switzerland, Japan and Australia </i></li><li><i>With seven biosimilars already approved globally, Sandoz will focus on progressing robust pipeline to enable early and expanded patient access and healthcare savings ?</i></li></ul><p><b>?</b></p><p><b>Holzkirchen, Germany, November 2, 2018 </b>— Sandoz, a Novartis division and the pioneer and global ...</p> Nov 02, 2018 21666 Sandoz receives US FDA approval for biosimilar Hyrimoz? (adalimumab-adaz) http://www.alloftv.com/news/media-releases/sandoz-receives-us-fda-approval-biosimilar-hyrimoz-adalimumab-adaz <ul><li><i>Biosimilar Hyrimoz? (adalimumab-adaz) approved for all indications of reference medicine not protected by orphan exclusivity<sup> ?</sup></i></li><li><i>Biosimilars are critical to sustaining US healthcare system, providing broader access to vital treatments for prevalent chronic conditions such as psoriasis and rheumatoid arthritis, which affect over eight million Americans combined</i></li><li><i>Hyrimoz<sup></sup>is third FDA-approved Sandoz biosimilar in US</i></li></ul><p><i>?</i></p><p><b>Holzkirchen, Germany, October 31, 2018 </b>— Sandoz, a Novartis division and the pioneer ...</p> Oct 31, 2018 21656 Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth http://www.alloftv.com/news/media-releases/novartis-delivered-strong-growth-and-innovation-during-third-quarter-including <ul type="disc"><li><b>Net sales grew 6% (cc[1], +3% USD) mainly driven by:</b><br /><ul type="circle"><li><em>Cosentyx</em> grew to USD 750 million (+37% cc) with strong volume growth across indications</li><li><em>Entresto</em> more than doubled to USD 271 million (+113% cc) driven by continued uptake worldwide</li><li><em>Promacta/Revolade</em> USD 295 million (+32% cc), <em>Tafinlar</em> + <em>Mekinist</em> USD 291 million (+33% cc) and <em>Jakavi</em> USD 248 million (+27% cc) continued strong double-digit growth</li><li>AAA sales of USD 105 million, driven by the strong launch of <em> ...</em></li></ul></li></ul> Oct 18, 2018 21641 Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access http://www.alloftv.com/news/media-releases/sandoz-announces-global-resolution-biosimilar-adalimumab-patent-disputes <ul type="disc"><li><i>Global resolution secures patient access to Sandoz biosimilar Hyrimoz<sup>?</sup> (adalimumab)[1] for the reference medicine Humira<sup>?</sup></i>**</li><li><i>Resolution paves way for 2018 launch in key European markets and secures US market entry planned in 2023</i></li></ul><p><b>Holzkirchen, October 11, 2018 </b>- Sandoz, a Novartis division and the global leader in biosimilars, today announced a global resolution of all intellectual property (IP) related litigation with AbbVie concerning the proposed Sandoz biosimilar Hyrimoz<sup>?</sup> (adalimumab)[1] for ...</p> Oct 11, 2018 21631 Sandoz Healthcare Access Challenge (HACk) returns, seeking digital solutions to local healthcare access challenges http://www.alloftv.com/news/media-releases/sandoz-healthcare-access-challenge-hack-returns-seeking-digital-solutions-local <ul><li><em>Despite major advances in modern medicine, universal access to healthcare remains the largest unmet medical need </em></li><li><em>Building on the inaugural Sandoz HACk, this year’s competition expands to seek broader digital solutions to local healthcare access challenges</em></li><li><em>Three shortlisted entrants will attend South by Southwest (SXSW), where Sandoz will work with them to create scalable solutions that could improve people’s lives</em></li></ul><p><strong>Holzkirchen, October 4, 2018 -</strong> Sandoz, the Novartis generics and biosimilars division, today ...</p> Oct 04, 2018 21621 Sandoz receives positive CHMP opinion for proposed biosimilar pegfilgrastim http://www.alloftv.com/news/media-releases/sandoz-receives-positive-chmp-opinion-proposed-biosimilar-pegfilgrastim <ul type="disc"><li><i>Positive opinion is based on comprehensive data confirming that Sandoz biosimilar pegfilgrastim matches the reference medicine in terms of safety, efficacy and quality</i></li><li><i>Sandoz seeks approval in the same indication as the reference medicine, to reduce the duration of neutropenia and the incidence of febrile neutropenia due to chemotherapy, some of the most serious side effects of cancer chemotherapy[1]</i></li><li><i>Sandoz is the global leader in biosimilars and continues to improve patient access and support sustainable healthcare with seven</i> <i> ...</i></li></ul> Sep 21, 2018 21596 Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo http://www.alloftv.com/news/media-releases/novartis-divest-sandoz-us-dermatology-business-and-generic-us-oral-solids <ul><li><i>Novartis to focus Sandoz division in US on higher growth areas and will sell selected portions of the Sandoz US portfolio to Aurobindo Pharma USA Inc.</i><br />?</li><li><i>Agreement comprises the Sandoz US generic oral solids and Sandoz US dermatology businesses with approximately 300 products and H1 2018 sales of USD 0.6 billion</i><br />?</li><li><i>Transaction supports the Sandoz strategy of focusing on complex generics, value-added medicines and biosimilars to achieve sustainable and profitable growth in the US </i></li></ul><p><b>Basel, September 6, 2018</b> <b>- </b>Novartis ...</p> Sep 06, 2018 21591 Sandoz receives European Commission approval for biosimilar Hyrimoz? (adalimumab) http://www.alloftv.com/news/media-releases/sandoz-receives-european-commission-approval-biosimilar-hyrimozr-adalimumab <ul type="disc"><li><i>Biosimilar Hyrimoz<sup>? </sup>(adalimumab) approved for use in all same indications as reference medicine</i>**<i>* including rheumatology, gastroenterology and dermatology </i></li><li><i>Early therapeutic intervention is essential in rheumatoid arthritis, supporting urgency of treatments like Hyrimoz</i></li><li><i>Fourth Sandoz biosimilar approved in Europe** in past 18 months, and seventh in total, underscoring Sandoz commitment to making access happen </i><i>through a robust portfolio</i></li></ul><p><b>Holzkirchen, July 27, 2018</b> - Sandoz, a Novartis division ...</p> Jul 27, 2018 21551 Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company http://www.alloftv.com/news/media-releases/novartis-delivers-solid-growth-second-quarter-and-continues-transformation <ul type="disc"><li><b>Net sales grew 5% (cc[1], +7% USD) mainly driven by:</b><br /><ul type="circle"><li><em>Cosentyx</em> grew to USD 701 million, (+40% cc) with strong growth in all indications in the US and EU</li><li><em>Entresto</em> sales more than doubled to USD 239 million, (+113% cc) driven by continued uptake worldwide</li><li>Oncology grew 10% (cc) driven by continued growth from <em>Promacta/Revolade</em>, <em>Tafinlar</em> + <em>Mekinist</em> and <em>Jakavi</em>, uptake of <em>Kisqali</em> and <em>Kymriah</em> and contribution from the AAA acquisition</li></ul></li><li><b>Core[ ...</b></li></ul> Jul 18, 2018 21546 Sandoz presents new long-term and switching data for biosimilars Zessly? (infliximab) and Erelzi? (etanercept) in rheumatoid arthritis http://www.alloftv.com/news/media-releases/sandoz-presents-new-long-term-and-switching-data-biosimilars-zesslyr-infliximab <ul type="disc"><li><i>Zessly</i><b><i><sup>?</sup></i></b><i> (infliximab) matched the reference medicine in terms of safety and efficacy at 54 weeks, even in patients who switched from the reference medicine to Zessly[1]</i></li><li><i>Switching from the reference medicine to Erelzi<sup>? </sup>(etanercept) did not impact efficacy and safety in patients with moderate to severe rheumatoid arthritis at 48 weeks[2]</i></li><li><i>Nearly 320 million people in Europe are expected to have limited access to disease-modifying anti-rheumatic medicines, underscoring the value of Zessly and Erelzi[3 ...</i></li></ul> Jun 15, 2018 21536 Sandoz receives positive CHMP opinion for proposed biosimilar adalimumab http://www.alloftv.com/news/media-releases/sandoz-receives-positive-chmp-opinion-proposed-biosimilar-adalimumab <ul><li><i>Sandoz is seeking approval of proposed biosimilar adalimumab for use in all reference medicine indications including those in rheumatology, gastroenterology and dermatology</i></li><li><i>Positive CHMP opinion based on comprehensive analytical, preclinical and clinical data package that shows proposed biosimilar adalimumab matches reference medicine </i></li><li><i>This recommendation marks the fourth positive CHMP opinion for a Sandoz biosimilar within 18 months </i></li></ul><p><b>Holzkirchen, June 1, 2018</b> – Sandoz, a Novartis division and the global leader in biosimilars, ...</p> Jun 01, 2018 21501 Sandoz receives European Commission approval for Zessly? (infliximab) in gastroenterological, rheumatological and dermatological diseases http://www.alloftv.com/news/media-releases/sandoz-receives-european-commission-approval-zesslyr-infliximab <p><strong>Sandoz receives European Commission approval for Zessly? (infliximab) in gastroenterological, rheumatological and dermatological diseases</strong></p><ul type="disc"><li><em>European Commission's (EC) approval based on comprehensive data package confirming that Zessly</em><em><sup>?</sup></em><em> matches safety, efficacy and quality of reference medicine</em></li><li><em>Biosimilars such as Zessly enable earlier patient access to important medicines and positively impact healthcare systems </em></li><li><em>Zessly is the third EC approval for a Sandoz biosimilar in 12 months ...</em></li></ul> May 24, 2018 21491 Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab http://www.alloftv.com/news/media-releases/sandoz-receives-complete-response-letter-us-fda-proposed-biosimilar-rituximab <p><strong>Holzkirchen, May 2, 2018 </strong>— Sandoz, a Novartis division, announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the Biologics Licensing Application (BLA) for its proposed biosimilar rituximab.</p><p>Sandoz stands behind the robust body of evidence included in the regulatory submission and is currently evaluating the content of the letter. While disappointed, Sandoz remains committed to further discussions with FDA in order to bring this important medicine to US patients as soon as possible.</p><p>There is a ...</p> May 02, 2018 21481 Novartis delivered a strong first quarter and acted to become a more focused medicines company http://www.alloftv.com/news/media-releases/novartis-delivered-strong-first-quarter-and-acted-become-more-focused-medicines <ul type="disc"><li><b>Net sales grew 4% (cc[1], +10% USD) mainly driven by:</b><br /><ul type="circle"><li><em>Entresto</em> grew to USD 200 million, +126% (cc) driven by increased uptake world wide</li><li><em>Cosentyx</em> was USD 580 million, +35% (cc) with strong growth in all indications and expanded access</li><li>Oncology returned to growth (+6% cc) driven by <em>Promacta/Revolade, Tafinlar + Mekinist, Jakavi</em> and recent launches</li></ul></li><li><b>Core[1] operating income grew 4% (cc, +11% USD) as higher sales helped support growth and launch investments; Core EPS of USD 1.28, ...</b></li></ul> Apr 19, 2018 21466 Sandoz signs agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics for patients with substance use disorder and opioid use disorders http://www.alloftv.com/news/media-releases/sandoz-signs-agreement-pear-therapeutics-develop-and-commercialize-prescription <ul><li><em>Deal includes reSET</em><sup>?</sup><em>, cleared by FDA for treatment of patients with Substance Use Disorder, and reSET-O</em><em>?,</em><em> potential treatment pending FDA clearance for patients with Opioid Use Disorder treated with buprenorphine? </em></li><li><em>Combines Sandoz expertise in launching / commercializing treatments with Pear's expertise in developing prescription digital therapeutics?</em></li><li><em>Sandoz and Novartis continue to embrace emerging digital technologies to enhance R&amp;D and deliver better outcomes for patients</em></li></ul><p><strong> ...</strong></p> Apr 18, 2018 21461 Sandoz outlines plans for next Healthcare Access Challenge (HACk), to support local digital innovation http://www.alloftv.com/news/media-releases/sandoz-outlines-plans-next-healthcare-access-challenge-hack-support-local <ul><li><em>Sandoz White Paper outlines importance of digital solutions to specific </em><em>local healthcare problems, as part of approach to increasing access to healthcare</em></li><li><em>Publication, which coincides with World Health Day 2018, outlines plans for expanded competition to “reimagine access to healthcare”</em></li><li><em>Upcoming HACk will draw strongly on learnings of past year; publication summarizes progress to date on three winning 2017 projects</em></li></ul><p><strong>Holzkirchen, April 7, 2018 </strong>– Sandoz today announces its continued commitment to improving ...</p> Apr 07, 2018 21421 Sandoz receives positive CHMP opinion for proposed biosimilar infliximab http://www.alloftv.com/news/media-releases/sandoz-receives-positive-chmp-opinion-proposed-biosimilar-infliximab <ul><li><em>Sandoz is seeking approval of biosimilar infliximab for use in all indications of its reference medicine across gastroenterology, rheumatology and dermatology</em></li><li><em>Positive opinion is based on comprehensive clinical and non-clinical data that is expected to confirm that Sandoz biosimilar infliximab matches the reference medicine </em></li><li><em>This recommendation marks the third CHMP positive opinion granted for a Sandoz biosimilar in 12 months following Erelzi<sup>? </sup>and Rixathon<sup>?</sup>; Sandoz is on track to launch several biosimilars of major oncology ...</em></li></ul> Mar 23, 2018 21416 Sandoz announces US FDA approval and launch of Glatopa? 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis http://www.alloftv.com/news/media-releases/sandoz-announces-us-fda-approval-and-launch-glatopar-40-mgml-three-times-week <ul type="disc"><li><i>Glatopa<sup>?</sup> 40 mg/mL is a fully substitutable, AP-rated generic version of Copaxone<sup>?*</sup> (glatiramer acetate injection) 40 mg/mL</i></li><li><i>Glatopa 40 mg/mL, along with Glatopa<sup>?</sup> 20 mg/mL, which was launched in the US in June 2015, will offer patients a complete range of dosing options</i></li><li><i>A full range of patient support services for Glatopa<sup>? </sup>is available through GlatopaCare<sup>?</sup></i></li></ul><p><b>Holzkirchen, February?</b><b>13</b><b>, 2018 </b>- Sandoz, a Novartis division, today announced the US FDA approval ...</p> Feb 13, 2018 21401 Sandoz certified as Top Employer Europe 2018 http://www.alloftv.com/news/media-releases/sandoz-certified-top-employer-europe-2018 <ul><li><em>Sandoz has been officially certified by the Top Employers Institute for its exceptional employee offerings in Europe and Russia</em></li><li><em>The annual, international research undertaken by the Top Employers Institute recognizes leading employers around the world</em></li><li><em>This exclusive certification underlines Sandoz′ commitment to attract and retain the best people from the industry</em></li></ul><p><strong>Holzkirchen, February 1, 2018 </strong>– Sandoz, a Novartis division, is proud to announce that it has officially been certified “TOP Employer Europe 2018” for ...</p> Feb 01, 2018 21391 Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase http://www.alloftv.com/news/media-releases/novartis-delivered-good-operational-performance-and-landmark-innovation-2017 <ul type="disc"><li><b>Full year sales grew 2% (cc, +1% USD) as strong performance of our growth drivers, including <i>Cosentyx</i> and<i> Entresto</i>, more than offset <i>Gleevec/Glivec</i> generic erosion: </b><br /><br /><ul type="circle"><li><i>Cosentyx</i> grew to USD 2.1 billion in 2017, USD 615 million in Q4</li><li><i>Entresto</i> grew to USD 507 million in 2017, USD 185 million in Q4</li><li>Oncology excluding <i>Gleevec/Glivec</i> grew 10% (cc)<i>, </i>with 13% (cc) growth in Q4</li></ul></li><li><b>Full year 2017 core[1] operating income was broadly in line with prior year (0% cc ...</b></li></ul> Jan 24, 2018 21386 Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars http://www.alloftv.com/news/media-releases/sandoz-announces-exclusive-global-collaboration-biocon-next-generation <ul><li><em>Collaboration aims to help patients worldwide gain access to </em><em>a range of high-quality, affordable immunology and oncology biologics</em></li><li><em>Partnership will be an important part of Sandoz and Biocon strategy to address the next wave of biosimilar opportunities globally </em></li><li><em>Collaboration will leverage combined strengths of development, manufacturing and commercialization of biosimilars</em></li><li><em>Partnership provides foundation for expansion of portfolio? </em></li></ul><p><strong>Holzkirchen, 18 January 2018</strong> – Sandoz, a Novartis ...</p> Jan 18, 2018 21381 Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA http://www.alloftv.com/news/media-releases/sandoz-regulatory-submission-proposed-biosimilar-adalimumab-accepted-fda <ul><li><em>Adalimumab is an anti-TNF medicine used to treat a range of immunological diseases[1]</em></li><li><em>The comprehensive data package provided is expected to demonstrate that Sandoz proposed biosimilar adalimumab matches the reference biologic medicine in terms of safety, efficacy and quality[2]-[4] </em></li></ul><p><strong>Holzkirchen, January 16, 2018</strong> - Sandoz, a Novartis division and the global leader in biosimilar medicines, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA), submitted under the 351 (k ...</p> Jan 16, 2018 21371 Sandoz announces new Phase I data showing proposed biosimilar pegfilgrastim matches reference medicine http://www.alloftv.com/news/media-releases/sandoz-announces-new-phase-i-data-showing-proposed-biosimilar-pegfilgrastim <ul><li><em>Phase I study demonstrates matching pharmacokinetic (PK), pharmacodynamic (PD), safety and immunogenicity profiles of Sandoz biosimilar pegfilgrastim and reference medicine </em></li><li><em>Pegfilgrastim is a long-acting version of the oncology supportive care medicine filgrastim </em></li></ul><p><strong>Holzkirchen, 08 December 2017</strong>– Sandoz, a division of Novartis ?and the global leader in biosimilars, today announced data demonstrating the pharmacokinetics (PK), pharmacodynamics (PD), safety and immunogenicity of proposed biosimilar pegfilgrastim as compared to the ...</p> Dec 08, 2017 21351 Sandoz Scientific Standalone Event in Russia “Combat Infections to Save Lives” http://www.alloftv.com/news/media-releases/sandoz-scientific-standalone-event-russia-combat-infections-save-lives <ul><li><em>Sandoz Scientific Standalone Event “Combat Infections to Save Lives” aims at increasing access to information in the field of antibiotic therapies in Central &amp; Eastern Europe and Middle East &amp; Africa (CEEMEA) </em></li><li><em>First event in the field of anti-infectives is utilizing digital platforms to reach healthcare professionals with state-of-art information shared by internationally recognized and trusted experts.</em></li></ul><p><strong>Holzkirchen, November 15, 2017</strong> <strong>– </strong>Sandoz is holding today a Scientific Standalone Event “Combat ...</p> Nov 15, 2017 21331 New data reinforces clinical basis for switching to Sandoz biosimilar medicines http://www.alloftv.com/news/media-releases/new-data-reinforces-clinical-basis-switching-sandoz-biosimilar-medicines <ul><li><i>Sandoz strengthens position as global leader in biosimilars with new immunology data from four clinical studies for proposed biosimilars adalimumab and rituximab</i></li><li><i>Efficacy and safety of biosimilar adalimumab and safety of biosimilar rituximab match reference medicines in multiple-switching and retreatment study respectively? </i></li><li><i>Sandoz biosimilar adalimumab is under EMA review, while EC-approved Sandoz biosimilar rituximab is under review by the FDA</i></li></ul><p><b>Holzkirchen, November 14, 2017</b>- Sandoz, a Novartis division and the global leader in ...</p> Nov 14, 2017 21326 Sandoz proposed biosimilar pegfilgrastim accepted by EMA for regulatory review http://www.alloftv.com/news/media-releases/sandoz-proposed-biosimilar-pegfilgrastim-accepted-ema-regulatory-review <ul><li>Comprehensive data package demonstrates that Sandoz biosimilar pegfilgrastim matches the reference biologic in terms of safety, efficacy and quality</li><li>Pegfilgrastim is a long-acting version of oncology medicine filgrastim -- Sandoz is the European market leader for filgrastim ?</li><li>Sandoz is the global leader in biosimilars, with five biosimilars marketed worldwide and a leading global pipeline, including three biosimilars currently under EMA review</li></ul><p><strong>Holzkirchen, October 27, 2017</strong> – Sandoz, a Novartis Division, and the global leader in biosimilars ...</p> Oct 27, 2017 21291 Novartis delivered growth on top and bottom line in all divisions in Q3 http://www.alloftv.com/news/media-releases/novartis-delivered-growth-top-and-bottom-line-all-divisions-q3 <ul type="disc"><li><strong>Net sales grew 2% (cc[1], +2% USD), with growth in all divisions: </strong><br /><ul type="circle"><li><i>Cosentyx</i> (USD 556 million, +83% cc) showed strong growth across all indications</li><li><i>Entresto </i>(USD 128 million, +138% cc) grew driven by improved access and US sales force expansion</li><li>Excluding <i>Gleevec/Glivec</i>, Oncology grew 11% (cc)</li><li>Alcon was up 7%[2] (cc) with strong growth in Surgical and continued growth in Vision Care</li><li>Sandoz grew 1% (cc) driven by growth outside the US, fully offsetting US price pressure</li> ...</ul></li></ul> Oct 24, 2017 21281 Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study http://www.alloftv.com/news/media-releases/sandoz-proposed-biosimilar-adalimumab-matches-reference-biologic-terms-efficacy <ul><li><em>51-week clinical study confirms that ?Sandoz proposed biosimilar adalimumab matches reference medicine Humira<sup>?*</sup> safety and efficacy profile<sup>1</sup></em></li><li><em>Sandoz proposed biosimilar adalimumab is currently under review by the European Medicines Agency for the treatment of several immunological diseases</em></li><li><em>Sandoz expects that approval of biosimilar adalimumab would further improve access to treatment for people living with immunological diseases</em></li></ul><p><em>?</em><strong>Holzkirchen, September 14, 2017</strong> – Sandoz, a Novartis ...</p> Sep 14, 2017 21201 Sandoz proposed biosimilar rituximab accepted for review by the FDA http://www.alloftv.com/news/media-releases/sandoz-proposed-biosimilar-rituximab-accepted-review-fda <ul><li><em>Rituximab is indicated to treat blood cancers and immunological diseases such as rheumatoid arthritis<sup>1</sup></em></li><li><em>Sandoz believes the comprehensive data package submitted to the FDA for review confirms that our biosimilar rituximab matches the reference medicine in terms of safety, efficacy and quality</em></li><li><em>The global leader in biosimilars, </em><em>Sandoz has five biosimilars approved worldwide including biosimilar rituximab, which was approved in Europe* in June 2017<sup>2</sup></em></li></ul><p><strong>Holzkirchen, September 12, 2017</strong> – ...</p> Sep 12, 2017 21196 Sandoz invests in major expansion of global headquarters in Holzkirchen, Germany http://www.alloftv.com/news/media-releases/sandoz-invests-major-expansion-global-headquarters-holzkirchen-germany <ul><li><em>Expected investment will amount to approximately USD 50m</em></li><li><em>Decision to expand underlines confidence in growth potential of business</em></li><li><em>Modern campus facility will promote more collaborative ways of working </em></li></ul><p><strong>Holzkirchen, August 29, 2017</strong> — Sandoz, the generic pharmaceuticals and biosimilars division of Novartis, announced today that it will further expand its global headquarters in Holzkirchen, near Munich. The expected investment will amount to approximately USD 50m.</p><p>Sandoz will begin construction of two ...</p> Aug 29, 2017 21181 Lancet Haematology publishes data demonstrating Sandoz Rixathon? (biosimilar rituximab) matches efficacy and safety of reference biologic http://www.alloftv.com/news/media-releases/lancet-haematology-publishes-data-demonstrating-sandoz-rixathonr-biosimilar <ul><li><em>Lancet Haematology publishes data from ASSIST-FL study of Sandoz Rixathon?, in patients with previously untreated advanced follicular lymphoma</em></li><li><em>ASSIST-FL, results of which were first announced in December 2017, achieved its primary endpoint1</em></li><li><em>Rixathon? received European Commission approval for use in all indications of the reference biologic in June 2017 <sup>2,3</sup></em></li></ul><p><strong>Holzkirchen, August 29, 2017 </strong>– <em>Lancet Haematology </em>has published data from the ASSIST-FL trial demonstrating that the efficacy and safety of ...</p> Aug 29, 2017 21171 Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries http://www.alloftv.com/news/media-releases/sandoz-expands-partnership-world-child-cancer-help-children-access-treatment <ul type="disc"><li><i>Expanded partnership to help "even the odds" of survival for children with cancer in the Philippines, Myanmar, Mexico and Ghana</i></li><li><i>In developed countries, the survival rate for childhood cancer is 80%, while in developing countries it can be as low as 10%</i></li><li><i>Sandoz is committed to working with key stakeholders to pioneer novel ways of expanding access to healthcare</i></li></ul><p align="left"><strong>The digital press release with multimedia content can?be accessed here:?</strong></p><p align="center"><br /><strong> ...</strong></p> Jul 25, 2017 21151 Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products http://www.alloftv.com/news/media-releases/q2-results-confirm-full-year-guidance-strong-pipeline-results-underpin-potential <ul><li><b>Net sales in line with prior year (0% cc[1], -2% USD), as growth drivers offset <i>Gleevec/Glivec </i>Gx impact:</b><ul><li><i>Cosentyx</i> (USD 490 million, +90% cc) continues strong growth in all three indications</li><li><i>Entresto </i>(USD 110 million) grew steadily driven by improved access and US sales force expansion</li><li>Excluding <i>Gleevec/Glivec, </i>Oncology grew 9% (cc), driven by <i>Promacta, Tafinlar + Mekinist ?</i>and <i>Jakavi </i></li><li>Sandoz declined 4% (cc) mainly impacted by increased US pricing pressure</li><li>Alcon grew 3% (cc) driven by Surgical (+3 ...</li></ul></li></ul> Jul 18, 2017 21141 FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus? http://www.alloftv.com/news/media-releases/fda-accepts-sandoz-regulatory-submission-generic-version-advair-diskusr <ul type="disc"><li><i>FDA accepts Sandoz ANDA for substitutable generic version of Advair Diskus</i><sup>?</sup></li><li><i>Sandoz believes its combination product will offer asthma and COPD patients same safety and efficacy as reference medicine</i></li><li><i>Sandoz looks forward to working with FDA to drive access to this treatment option</i></li></ul><p><b>Holzkirchen, June 15, 2017- </b>Sandoz today announced that the US Food and Drug Administration (FDA) has accepted its Abbreviated New Drug Application for fluticasone propionate / salmeterol combination product, a substitutable ...</p> Jun 15, 2017 21126 Sandoz receives approval in Europe for Erelzi? (biosimilar etanercept) to treat multiple inflammatory diseases http://www.alloftv.com/news/media-releases/sandoz-receives-approval-europe-erelzir-biosimilar-etanercept-treat-multiple <ul><li><em>European Commission approves Sandoz Erelzi<sup>?</sup> to treat immunological diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis</em></li><li><em>Approval of Erelzi provides more treatment options for healthcare professionals and patients and opens another chapter in the Sandoz immunology portfolio</em></li><li><em>Sandoz now has five biosimilars approved in Europe, including biosimilars of some of the world’s leading blockbuster biologics</em><em><sup>1</sup></em></li></ul><p><strong>Holzkirchen,</strong><strong> June 27, 2017 </strong>— Sandoz, a Novartis ...</p> Jun 27, 2017 21121 Sandoz receives approval in Europe for Rixathon? (biosimilar rituximab) to treat blood cancers and immunological diseases http://www.alloftv.com/news/media-releases/sandoz-receives-approval-europe-rixathonr-biosimilar-rituximab-treat-blood <ul><li><em>European Commission approves Sandoz Rixathon<sup>?</sup> to treat blood cancers and immunological diseases.</em></li><li><em>Approval expected to broa</em><em>den patient access to biologics and enable budget-constrained healthcare systems to reallocate resources to other healthcare priorities.</em></li><li><em>Sandoz now has four biosimilars approved in Europe — more than any other company.<sup>1</sup></em></li></ul><p><strong>Holzkirchen, June 19, 2017 </strong>— Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, announced today that the European ...</p> Jun 19, 2017 21111 US Supreme Court rules in favor of Sandoz in biosimilars case, enabling earlier access to potentially life-saving medicines http://www.alloftv.com/news/media-releases/us-supreme-court-rules-favor-sandoz-biosimilars-case-enabling-earlier-access <ul><li>US Supreme Court rules that six months' notice of commercial marketing can be given prior to FDA approval in Sandoz vs. Amgen</li><li>Justices also provided much needed clarity on the patent litigation process, often referred to as the ‘patent dance’</li><li>As the first company to gain approval for and launch a biosimilar under the BPCIA's new regulatory pathway, Sandoz continues to pioneer the path forward for these high-quality, cost-effective medicines in the US</li></ul><p><strong>Holzkirchen, 13 June 2017</strong> – Sandoz, a Novartis division, today announced that the Supreme ...</p> Jun 13, 2017 21106 US Supreme Court clears way to early access to biosimilars http://www.alloftv.com/news/media-releases/us-supreme-court-clears-way-early-access-biosimilars <p>“Biosimilars offer significant value to patients, providers and payers, increasing the number of treatment options available to patients across many disease areas at a reduced cost to the healthcare system.? The Justices’ unanimous ruling on the notice of commercial marketing will help expedite patient access to life-enhancing treatments. We also appreciate the clarity provided on the patent dance, which will help the biosimilars industry move forward,” said Carol Lynch, Global Head of Biopharmaceuticals, Sandoz. “As the global leader in biosimilars, it is our responsibility to help ...</p> Jun 12, 2017 21101 At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018 http://www.alloftv.com/news/media-releases/meet-novartis-management-investor-event-novartis-highlights-focus-innovation-and <ul><li><i>Building depth across key therapeutic areas with 12 potential blockbusters in late stage development and 40 potential filings in US and EU between 2017-2020</i></li><li><i><i>Focused and taking steps to become stronger and more integrated through centralized manufacturing, development and business services </i></i></li><li><i><i><i>Poised for next growth phase, anticipated to begin in 2018</i></i></i></li></ul><p><b>Boston, May 31, 2017</b><i> <b>- </b></i>Today Novartis holds its fourth annual Meet Novartis Management event at its research headquarters in Cambridge, MA, giving ...</p> May 31, 2017 21076 Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines Agency http://www.alloftv.com/news/media-releases/sandoz-proposed-biosimilars-adalimumab-and-infliximab-accepted-regulatory-review <ul><li><em>Sandoz is seeking approval for their proposed biosimilars adalimumab and infliximab for use in all indications of their respective reference medicines, Humira?* and Remicade?</em><em>?</em></li><li><em>Comprehensive data packages demonstrate each biosimilar matches its respective reference medicine in terms of quality, efficacy and safety</em></li><li><em>These regulatory submissions follow soon after two positive CHMP opinions** for Sandoz biosimilars etanercept and rituximab further reinforcing Sandoz immunology pipeline and the broader Novartis immunology portfolio</em></li> ...</ul> May 31, 2017 21071 Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued http://www.alloftv.com/news/media-releases/novartis-delivered-sales-growth-across-all-divisions <ul><li><b>Net sales grew 2% (cc, -1% USD), as growth drivers more than offset Gleevec/Glivec impact</b><ul><li>Cosentyx (USD 410 million, +136% cc) showing strong growth in all three indications</li><li>Entresto (USD 84 million) steadily growing with better access in US and EU</li><li>Gilenya (USD 722 million, +5% cc) grew mainly driven by volume</li><li>Excluding Gleevec/Glivec, Oncology grew +7% (cc) driven mainly by Promacta/Revolade, Jakavi, Tafinlar + Mekinist and Tasigna</li></ul></li><li><b>Core[1] operating income down 5% (cc) due to generic erosion and increased investments, mainly ...</b></li></ul> Apr 25, 2017 21046 Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe* http://www.alloftv.com/news/media-releases/sandoz-proposed-biosimilars-rituximab-and-etanercept-recommended-approval-europe <ul><li><em>Sandoz receives positive CHMP opinions for biosimilars rituximab and etanercept to treat immunological diseases. ?Biosimilar rituximab also recommended to treat blood cancers</em></li><li><em>Comprehensive data packages, confirming Sandoz biosimilars rituximab and etanercept match their respective reference medicines, were the basis for CHMP decisions </em></li><li><em>Subject to EC** approval, Sandoz market leadership position extended as the only company to have five approved biosimilars in Europe<sup>1</sup></em></li></ul><p><strong>Holzkirchen, April 21, 2017 </strong>– Sandoz ...</p> Apr 21, 2017 21036 Major Novartis investment in Slovenia reinforces commitment to largest Sandoz product and business http://www.alloftv.com/news/media-releases/major-novartis-investment-slovenia-reinforces-commitment-largest-sandoz-product <ul><li><em>Total investment of EUR 105 million in Prevalje site reinforces commitment to largest Sandoz business, Anti-Infectives, and single largest global product, broad-spectrum antibiotic amoxicillin-clavulanic acid.</em></li><li><em>The investment will bring 150 new jobs, more than doubling the number of employees at Prevalje over six years. </em></li><li><em>The project, scheduled for completion in 2019, will be the largest Novartis investment in Slovenia to date.</em></li></ul><p><strong>Prevalje, April 11, 2017</strong> – A foundation stone for the new production plant for a broad- ...</p> Apr 11, 2017 21031 Sandoz digital “Scientific Standalone” event will help drive access to medical information in field of cardiovascular therapies http://www.alloftv.com/news/media-releases/sandoz-digital-scientific-standalone-event-will-help-drive-access-medical <ul><li><em>Sandoz Scientific Standalone event -- “Reach Targets, Save Lives” – aims at increasing access to information in the field of cardiovascular therapies in Central &amp; Eastern Europe and Middle East &amp; Africa (CEEMEA)</em></li><li><em><em>Lectures by leading cardiologists and internal medicine specialists will be recorded and offered for re-use across the region following the live event</em></em></li><li><em><em><em>Enhanced digital training can help improve health outcomes for patients</em></em></em></li></ul><p>?</p><p><strong>Holzkirchen, March 20, 2017</strong> <strong>– ...</strong></p> Mar 20, 2017 20986 Sandoz announces winners of inaugural Healthcare Access Challenge (Sandoz HACk) http://www.alloftv.com/news/media-releases/sandoz-announces-winners-inaugural-healthcare-access-challenge-sandoz-hack <ul><li> <i>Three winners, chosen by expert panel at Wired Health 2017 in London, identified innovative approaches to address access challenges in Ghana, the Maldives and the Philippines.</i> </li><li> <i>Winning ideas proposed novel ways to use mobile technologies to connect patients with caregivers and essential medicines</i> </li><li> <i>Sandoz invited young people worldwide to "reimagine access to healthcare" - arguably the largest unmet medical need </i> </li></ul><p><b>London, March 13, 2017 </b>- Sandoz, a Novartis Division, announced today the three winners of the inaugural Healthcare ...</p> Mar 13, 2017 20961 New data demonstrate Sandoz proposed biosimilar adalimumab has equivalent efficacy to reference medicine http://www.alloftv.com/news/media-releases/new-data-demonstrate-sandoz-proposed-biosimilar-adalimumab-has-equivalent <ul><li>Sandoz proposed biosimilar adalimumab (GP2017) shown to have equivalent efficacy and a similar safety profile as reference medicine, Humira<sup>?</sup>*</li><li>Comprehensive development program show potential of GP2017 to treat inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis</li><li>Study reinforces strength of Sandoz pipeline and its key role in the broader Novartis immunology portfolio</li></ul><p><strong>Holzkirchen, 6 March 2017</strong> – Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today ...</p> Mar 06, 2017 20956 Sandoz confirms strategic commitment to drive access to medicines in Japan, with plan to double business by 2022 http://www.alloftv.com/news/media-releases/sandoz-confirms-strategic-commitment-drive-access-medicines-japan <ul><li><em>Japanese generic market set to expand rapidly, driven by government commitment to achieving sustainable high-quality healthcare</em></li><li><em>Sandoz Japan plans 70 new launches over next six years, which will account<br />for ~40% of total sales by 2022</em></li><li><em>Growth drivers will include oncology, CNS and biosimilars</em></li></ul><p><strong>Tokyo, February 8, 2017</strong> <strong>– </strong>Sandoz plans to double sales in Japan over the 2015 to 2022 period, as part of its long-term strategic plan to help drive access to hiqh-quality medicines in the Japanese market ...</p> Feb 07, 2017 20916 Sandoz certified as Top Employer Europe 2017 http://www.alloftv.com/news/media-releases/sandoz-certified-top-employer-europe-2017 <ul><li><em>Sandoz has been officially certified ?by the Top Employers Institute for its exceptional employee offerings in Europe</em></li><li><em>The annual, international research undertaken by the Top Employers Institute recognizes leading employers around the world</em></li><li><em>This exclusive certification underlines our determination to attract and retain the best people from inside and outside our industry.”</em></li></ul><p><strong>Holzkirchen, February 8, 2017 </strong>– Sandoz, a Novartis division, is proud to announce that it has been officially certified ?by the Top Employers ...</p> Feb 08, 2017 20911 Novartis delivered solid 2016 performance, with Growth Products[1] absorbing Gleevec US LOE; innovation momentum continued; announces share buyback http://www.alloftv.com/news/media-releases/novartis-delivered-solid-2016-performance-growth-products1-absorbing-gleevec-us <ul><li><b>FY net sales (0% cc[2]) in line with prior year due to strong Growth Products performance </b><ul><li><i>Cosentyx</i> (USD 1.1 billion) reached blockbuster status</li><li><i>Entresto </i>(USD 170 million) continued to grow steadily, following positive treatment guidelines in US and Europe and ongoing US field force expansion</li><li><i>Gilenya </i>(USD 3.1 billion, +14% cc) delivered double-digit growth</li><li>Oncology grew 12% (cc) excluding<i> Gleevec/Glivec</i>, driven by new assets and <i>Jakavi</i></li><li>Sandoz Biopharmaceuticals[1] grew 31% (cc) to reach USD 1.0 billion ...</li></ul></li></ul> Jan 25, 2017 20906 New interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product http://www.alloftv.com/news/media-releases/new-interim-data-demonstrate-sandoz-proposed-biosimilar-rituximab-has-equivalent <ul><li>ASSIST-FL trial demonstrates equivalent safety, efficacy, pharmacokinetics and pharmacodynamics of Sandoz proposed biosimilar rituximab (GP2013) to the reference product[1]</li><li>Interim data in over 600 adults show potential of GP2013 as an alternative rituximab[1]</li><li>Sandoz proposed biosimilar rituximab is the company's first monoclonal antibody candidate</li></ul><p><strong>Holzkirchen, December 5, 2016</strong> - Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced data from the ASSIST-FL trial. The confirmatory safety and efficacy ...</p> Dec 05, 2016 20846 Sandoz to donate up to USD 10 million of high-quality generic medicines annually to Americares to increase access to medicines http://www.alloftv.com/news/media-releases/sandoz-donate-usd-10-million-high-quality-generic-medicines-annually-americares <p><strong>Princeton, New Jersey, November 22, 2016. </strong>Sandoz today announced a collaboration to increase access to medicines by donating up to USD 10 million of stock annually to Americares, a health-focused relief and development organization that responds to people affected by poverty or disaster with life-changing health programs, medicine and medical supplies.</p><p>The initial donation will include over 25 Sandoz products for treatment for infections, cardiovascular conditions, eyecare, skin conditions and musculoskeletal pain. It is part of the global Sandoz commitment to ...</p> Nov 22, 2016 20746 Innovative study with three treatment switches confirms Sandoz biosimilar etanercept has equivalent efficacy to originator http://www.alloftv.com/news/media-releases/innovative-study-three-treatment-switches-confirms-sandoz-biosimilar-etanercept <ul type="disc"><li><em>No clinically meaningful differences between biosimilar etanercept and the originator product in safety and efficacy over 52 weeks[1]</em></li><li><em>Innovative study design demonstrates switching between biosimilar etanercept and the originator product has no impact on safety and efficacy[1]</em></li><li><em>Sandoz biosimilar etanercept was approved by the FDA* in August 2016 and is currently under review by the EMA</em>**</li></ul><p><strong>Holzkirchen, November 18, 2016</strong> - Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today ...</p> Nov 18, 2016 20741 Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters http://www.alloftv.com/news/media-releases/novartis-delivered-solid-third-quarter-growth-products1-offsetting-gleevec <ul><li><strong>Q3 net sales (-1% cc[2] and USD) broadly in line with prior year due to strong performance of Growth Products </strong><ul><li><em>Gilenya </em>(USD 790 million, +15% cc) continued double-digit growth</li><li><em>Cosentyx</em> (USD 301 million) on track for blockbuster status in first full year after approval</li><li>Oncology growth drivers including<em> Tafinlar + Mekinist </em>(USD 172 million, +29% cc), <em>Promacta/Revolade</em> (USD 168 million, +44% cc) and <em>Jakavi</em> (USD 149 million, +47% cc)</li><li>Sandoz Biopharmaceuticals[1] (USD 262 million, +41% cc) ...</li></ul></li></ul> Oct 25, 2016 20701 Sandoz invites young entrepreneurs to enter Sandoz HACk, a global competition to help solve healthcare access challenges http://www.alloftv.com/news/media-releases/sandoz-invites-young-entrepreneurs-enter-sandoz-hack-global-competition-help <ul><li><em>Despite significant advances made by modern medicine, universal access to healthcare is still arguably the single largest unmet medical need</em></li><li><em>Sandoz “HACk” – Healthcare Access Challenge – is a competition seeking young people with innovative ideas to “reimagine” access to healthcare</em></li><li><em>Sandoz HACk is partnering with OpenIDEO – a global community that drives collaboration, innovation and impact around the world's toughest problems</em></li></ul><p><strong>Holzkirchen, September 28, 2016</strong>?– Sandoz, the Novartis generic and biosimilar ...</p> Sep 28, 2016 20611 Top-line results for PF-06438179 (biosimilar infliximab) demonstrate equivalent efficacy to reference product http://www.alloftv.com/news/media-releases/top-line-results-pf-06438179-biosimilar-infliximab-demonstrate-equivalent <ul><li>Sandoz, a Novartis division, the pioneer and global leader in biosimilars acquired the rights from Pfizer for the development, commercialization and manufacture of PF-06438179 in the 28 countries that form the European Economic Area (EEA)* in February 2016 where it is known as GP1111.</li><li>The confirmatory study (REFLECTIONS B537-02), evaluating the efficacy, safety and immunogenicity of PF-06438179 (biosimilar infliximab) to reference product Remicade? (infliximab), met its primary endpoint.</li><li>Results demonstrate equivalent efficacy as measured by the American College of ...</li></ul> Sep 16, 2016 20551 AirFluSal? Forspiro? showed superiority at 12 months over Seretide? Diskus?[1] in persistence to treatment http://www.alloftv.com/news/media-releases/airflusalr-forspiror-showed-superiority-12-months-over-seretider-diskusr1 <ul><li><em>New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide? Diskus?.</em></li><li><em>Study highlights importance of improving treatment "persistence" over time for long-term respiratory diseases. </em></li><li><em>Analysis, published in leading medical journal, is largest European Real-World Evidence study ever conducted in asthma and COPD.</em></li></ul><p>[1] Seretide? and Diskus? are registered trademarks owned by Glaxo Group Ltd.</p><p><strong>Holzkirchen, August 31, 2016 </strong>- New data just ...</p> Aug 31, 2016 20491 FDA approves Sandoz Erelzi? to treat multiple inflammatory diseases http://www.alloftv.com/news/media-releases/fda-approves-sandoz-erelzitm-treat-multiple-inflammatory-diseases <ul type="disc"><li><em>Erelzi is approved for all indications included in the reference product's label</em><br />?</li><li><em>Erelzi is the first biosimilar etanercept approved by the FDA, offering expanded access to this important medicine</em><br />?</li><li><em>Erelzi is the second biosimilar from Sandoz to receive FDA approval in the US, building upon established global leadership in biosimilars</em></li></ul><p><strong>Holzkirchen, August 30, 2016 - </strong>Sandoz, a Novartis division and the global leader in biosimilars, announced today that the US Food and Drug Administration (FDA ...</p> Aug 30, 2016 20486 Launch of novel on-demand news service Transplant TODAY from TTS 2016 transplant congress http://www.alloftv.com/news/media-releases/launch-novel-demand-news-service-transplant-today-tts-2016-transplant-congress <ul><li>First-of-a-kind service for healthcare professionals will offer access to latest news from leading international transplantation congress.</li><li>Transplant TODAY online service will be launched at this month’s International Congress of the Transplantation Society (TTS).</li><li>Sandoz, the leading global supplier of generic transplantation medicines, collaborates with international experts to offer this service.</li></ul><p><strong>Holzkirchen, August 9, 2016 </strong>– Sandoz today announces the launch of a novel online medical education platform, Transplant TODAY, offering access ...</p> Aug 18, 2016 20456 Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects http://www.alloftv.com/news/media-releases/novartis-delivered-solid-q2-despite-full-quarter-us-gleevec-generic-impact <ul><li><strong>Q2 net sales were flat (0% cc[1]) as Growth Products[2] offset <em>Gleevec</em> generic impact </strong><ul><li><em>Gilenya </em>(USD 811 million, +17% cc) continued to grow double-digit mainly due to volume growth</li><li><em>Cosentyx</em> (USD 260 million) grew strongly driven by its three approved indications</li></ul></li><li><strong>Core[1] operating income declined (-4% cc) due to generic erosion and growth investments </strong><ul><li>Core M&amp;S expenses up 0.8 percentage points (cc) to 24.6% of sales, mainly driven by <em>Cosentyx</em>, <em>Entresto</em> and Alcon ...</li></ul></li></ul> Jul 19, 2016 19991 Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases http://www.alloftv.com/news/media-releases/sandoz-biosimilar-etanercept-recommended-fda-advisory-committee-approval-treat <ul><li>Committee votes unanimously in favor of the Sandoz proposed biosimilar etanercept for all approved indications of the reference product</li><li>Committee’s recommendation based on totality of evidence from global development program showing biosimilar etanercept is highly similar to Enbrel<sup>?*</sup></li></ul><p><b>Holzkirchen, 13 July, 2016.</b> Sandoz, a Novartis division and leader in biosimilars, announced today that the US Food and Drug Administration (FDA) Arthritis Advisory Committee recommended approval of its proposed biosimilar etanercept. The committee voted unanimously ( ...</p> Jul 13, 2016 19971 New data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator product http://www.alloftv.com/news/media-releases/new-data-shows-sandoz-biosimilar-etanercept-candidate-has-equivalent-efficacy <ul><li>The EGALITY study met its primary endpoint demonstrating equivalent efficacy of Sandoz biosimilar etanercept candidate to the originator product at week 12</li><li>As a first-of-its kind, the confirmatory clinical safety and efficacy study compares originator etanercept to a biosimilar candidate in psoriasis</li><li>Sandoz biosimilar etanercept has been accepted for review by the EMA* and FDA**</li></ul><p><strong>Holzkirchen, July 7, 2016</strong>?– Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from the EGALITY trial in which ...</p> Jul 07, 2016 19966 Sandoz announces plans for five major global biosimilar launches by 2020 http://www.alloftv.com/news/media-releases/sandoz-announces-plans-five-major-global-biosimilar-launches-2020 <ul><li>Progress on biosimilar pipeline paves way for five planned launches by 2020</li><li>Sandoz now plans a total of 11 biosimilar filings by end 2017 (EU and US) and has already delivered on six</li><li>Investments of more than USD 1 billion in state of-the-art biomanufacturing facilities, backed by industry-leading capabilities as part of Novartis, positions Sandoz to deliver biosimilars at unprecedented scale</li></ul><p><strong>Holzkirchen, June 20, 2016</strong> -?Sandoz, a Novartis Division and the global leader in biosimilars, plans to launch five biosimilars of major oncology and ...</p> Jun 20, 2016 19946 Novartis recognized among world's most sustainable companies in Corporate Knights Global 100 http://www.alloftv.com/news/media-releases/novartis-recognized-among-worlds-most-sustainable-companies-corporate-knights <p><strong>Basel, January 27, 2014</strong> -?Novartis is pleased to announce that it has been named among the 2014 Corporate Knights Global 100.</p><p>Corporate Knights announced the results of its 2014 Global 100 Most Sustainable Corporations in the World (Global 100) index today at the World Economic Forum in Davos.</p><p>"Our inclusion in the Global 100 list is a testimony to our longstanding commitment to corporate responsibility," said Joseph Jimenez, CEO of Novartis. "Being recognized among the top 100 sustainability performers in the world underscores that doing business responsibly ...</p> Jan 27, 2014 13156 Sandoz biosimilar filgrastim recommended for approval by FDA Oncologic Drugs Advisory Committee http://www.alloftv.com/news/media-releases/sandoz-biosimilar-filgrastim-recommended-approval-fda-oncologic-drugs-advisory <ul><li>Oncologic Drugs Advisory Committee (ODAC) votes in favor of recommending biosimilar filgrastim for approval in the US</li><li>Biosimilar filgrastim recommended to be approved for use in all requested indications</li><li>Committee's recommendation based on review of extensive data from analytical, non-clinical, clinical studies and post-marketing pharmacovigilance</li></ul><p><strong>Holzkirchen, January 7, 2015?</strong>-?Sandoz, a Novartis company, announced today that US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of its ...</p> Jan 07, 2015 13151 Sandoz brings together key French stakeholders to discuss biosimilars http://www.alloftv.com/news/media-releases/sandoz-brings-together-key-french-stakeholders-discuss-biosimilars <p>Sandoz, the global leader in biosimilars, recently hosted an event in Paris for key stakeholders to discuss strategic issues impacting biosimilars and help them better understand their vital role in the success of these important therapies in France.</p><p><a href="http://www.sandoz-biosimilars.com/en/mediacenter/statement/140708_Sandoz_brings_together_key_French_stakeholders_to_discuss_biosimilars.shtml" target="_blank">Read more</a></p> Jul 08, 2014 13136 Sandoz launches Airflusal? Forspiro? in Sweden, further driving patient access to innovative new respiratory inhaler http://www.alloftv.com/news/media-releases/sandoz-launches-airflusalr-forspiror-sweden-further-driving-patient-access <ul><li>Sweden is fourth European country to launch Sandoz’s award-winning new inhaler for patients with asthma and COPD</li><li>Sandoz Sweden launches both 50-500 and 50-250 microgram dosage forms, following national marketing authorization earlier this year</li><li>Airflusal Forspiro offers proven combination of salmeterol and fluticasone propionate in an innovative new device, co-developed with patients</li></ul><p><strong>Holzkirchen, June 23, 2014:</strong>?Sandoz today announced the launch in Sweden of Airflusal? Forspiro?, an innovative new inhaler for patients with asthma and/or ...</p> Jun 23, 2014 13121 Sandoz launches three new products in Japan, including authorized generics of valsartan and zoledronic acid http://www.alloftv.com/news/media-releases/sandoz-launches-three-new-products-japan-including-authorized-generics-valsartan <ul><li>Sandoz Japan launches valsartan, the first authorized generic ARB in Japan. Sandoz also launches authorized generic of Zometa? for i.v. infusion 4mg/5mL and generic version of Preminent? Tablets LD</li></ul><p><strong>Tokyo, June 20, 2014</strong>?Sandoz announces today the launch in Japan of three new products, including valsartan, a generic version of Novartis’ Diovan? Tablets, zoledronic acid, a generic version of Novartis’ Zometa? for i.v. infusion 4mg/5mL and Losarhyd (losartan potassium/hydrochlorothiazide), a generic version of MSD’s Preminent? Tablets LD.</p><p>Valsartan and ...</p> Jun 20, 2014 13116 GSK application for preliminary injunction withdrawn just before Cologne Court of appeals was to rule in the case http://www.alloftv.com/news/media-releases/gsk-application-preliminary-injunction-withdrawn-just-cologne-court-appeals-was <ul><li>GlaxoSmithKline withdraws application for preliminary injunction on German marketing and distribution of Sandoz’s award-winning AirFluSal? Forspiro?</li><li>GSK application withdrawn shortly before Cologne Court of Appeals was due to rule in the case, restoring German patient access to AirFluSal</li><li>Sandoz continues to roll out its innovative and cost-effective respiratory inhaler, co-developed with patients, in Europe and beyond</li></ul><p><strong>Holzkirchen, June 16, 2014:</strong>?Pharmaceutical company GlaxoSmithKline has withdrawn its application for a preliminary ...</p> Jun 16, 2014 13101 Sandoz France launches generic Nasonex? nasal spray, the first generic nasal corticoid on the French market http://www.alloftv.com/news/media-releases/sandoz-france-launches-generic-nasonexr-nasal-spray-first-generic-nasal <ul><li>French launch is latest milestone in roll-out of Sandoz respiratory portfolio – a key pillar of its strategy to bring differentiated generics to patients and payors worldwide</li><li>Mometasone Sandoz? is first French specialty generic medicine indicated for treatment of a respiratory condition together with an inhaler</li><li>Allergic rhinitis affects up to 25% of the population of Western Europe annually</li></ul><p><strong>Levallois-Perret, June 2, 2014 -</strong> Sandoz, the generic pharmaceuticals division of Novartis, today announces the launch in France of Mometasone Sandoz?, ...</p> Jun 10, 2014 13096 Sandoz enhances strategic relationship with Upsher-Smith through marketing agreement for potassium chloride products http://www.alloftv.com/news/media-releases/sandoz-enhances-strategic-relationship-upsher-smith-through-marketing-agreement <p><strong>Princeton, New Jersey, June 3, 2014 - </strong>Sandoz today announced an agreement with Upsher-Smith to obtain exclusive US distribution rights for its branded potassium chloride line of products, Klor-Con?, and market them under the Sandoz name, enhancing its strategic relationship.</p><p>“This agreement expands and strengthens our current relationship with Upsher-Smith and helps us create a leading potassium chloride business,” said Peter Goldschmidt, President of Sandoz Inc. “With our extensive distribution system, we will be able to improve patient access to these products, ...</p> Jun 04, 2014 13091 Sandoz launches generic version of key anti-depressant Cipralex? in several European countries http://www.alloftv.com/news/media-releases/sandoz-launches-generic-version-key-anti-depressant-cipralexr-several-european <p><strong>Holzkirchen, June 4, 2014 - </strong>Sandoz, the generic pharmaceuticals division of Novartis, today announced the launch in several European countries of generic escitalopram, an affordable and high-quality version of reference product Cipralex?.</p><p>The Sandoz product, which is available in all strengths approved for the reference product (5mg, 10mg, 15mg and 20mg), was launched initially in countries including Belgium, France, Germany, Italy, Sweden and Switzerland.</p><p>Nick Haggar, Head of Sandoz Western Europe, Middle East and Africa, said: “Sandoz is already a regional ...</p> May 15, 2014 13086 Novartis appoints Jeff George as Division Head, Alcon as Kevin Buehler retires; Richard Francis named as new Division Head, Sandoz http://www.alloftv.com/news/media-releases/novartis-appoints-jeff-george-division-head-alcon-kevin-buehler-retires-richard <p><strong>Basel, April 9, 2014 - </strong>New leaders to continue to build global scale and innovation power in two of the leading Novartis businesses</p><p>Novartis announced today the appointment of Jeff George as Division Head of Alcon, effective May 1, 2014. Mr. George succeeds Kevin Buehler who is retiring from the company after a distinguished 30 year career at Alcon, the global leader in eye care. As part of the planned transition, Mr. Buehler will provide management and strategic support on the Alcon business. The company thanks Mr. Buehler for his significant contributions to ...</p> Apr 09, 2014 13081 Sandoz launches first generic version of Taclonex? Ointment http://www.alloftv.com/news/media-releases/sandoz-launches-first-generic-version-taclonexr-ointment <p><strong>Princeton, New Jersey, April 1, 2014 - </strong>Sandoz today announced the US market introduction of its calcipotriene and betamethasone dipropionate ointment, the first generic version of Leo Pharma’s Taclonex? Ointment.</p><p>?Calcipotriene and betamethasone dipropionate ointment is a vitamin D analogue and corticosteroid combination product indicated for the topical treatment of psoriasis vulgaris in adults 18 years of age and older.</p><p>Psoriasis affects approximately 2% of the US population. Plaque psoriasis is the most common form of the condition. [1]</p><p>"Sandoz is ...</p> Apr 02, 2014 13076 Sandoz launches AirFluSal? Forspiro? in Norway http://www.alloftv.com/news/media-releases/sandoz-launches-airflusalr-forspiror-norway <p><strong>Holzkirchen, April 2, 2014 - </strong>Sandoz announces today that it is launching in Norway AirFluSal? Forspiro?, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).</p><p>?The product was first approved in Denmark on December 18th, 2013, with subsequent approvals in Germany, Belgium, Sweden, Hungary, Romania and Bulgaria. In February, Sandoz received its first marketing approval in Asia, with marketing authorization in South Korea.</p><p>In Norway, Sandoz is launching the 50/250μg and 50/500μg dosage forms for the continuous ...</p> Apr 02, 2014 13071 Sandoz launches generic version of PREVPAC? in the US http://www.alloftv.com/news/media-releases/sandoz-launches-generic-version-prevpacr-us <p><strong>Princeton, New Jersey, March 27, 2014 - </strong>Sandoz today announced the US launch of lansoprazole capsules, amoxicillin capsules, USP, and clarithromycin tablets, USP, a generic version of PREVPAC?<sup>1</sup>.</p><p>?This product is indicated for the eradication of H. pylori infection in patients with duodenal ulcer disease. It comprises amoxicillin and clarithromycin, which are antibiotic medicines, as well as lansoprazole, a proton pump inhibitor that helps decrease production of excess stomach acid<sup>2</sup>.</p><p>“Sandoz is proud to provide a generic version of this ...</p> Apr 02, 2014 13066 Vas Narasimhan to lead Sandoz'biosimilars business http://www.alloftv.com/news/media-releases/vas-narasimhan-lead-sandozbiosimilars-business <p><strong>Munich, Germany, March 27, 2014 - </strong>Sandoz announced today that Vasant (Vas) Narasimhan, MD, MPP, has been appointed Head of Sandoz Biopharmaceuticals &amp; Oncology Injectables effective April 1, 2014. Vas, currently Global Head of Development at Novartis Vaccines, succeeds Ameet Mallik who will take on a new leadership role at Novartis Oncology. Vas will be responsible for biosimilars, oncology injectables, the biotechnology contract manufacturing business, as well as Sandoz’ industry-leading biosimilars pipeline.</p><p>"I am deeply grateful for Ameet’s outstanding ...</p> Mar 31, 2014 13056 Sandoz receives approval for biosimilar filgrastim in Japan http://www.alloftv.com/news/media-releases/sandoz-receives-approval-biosimilar-filgrastim-japan <ul><li>Sandoz Filgrastim approved in all indications as the reference product</li><li>Sandoz becomes first company to secure approval for two biosimilars in Japan</li><li>Approval marks continued expansion of Sandoz’ biosimilar business</li></ul><p></p><div class="media-youtube-video media-element file-default media-youtube-1"> ...</div> Mar 24, 2014 13036 Sandoz associates join Novartis Community Partnership Day 2014 http://www.alloftv.com/news/media-releases/sandoz-associates-join-novartis-community-partnership-day-2014 <p><strong>Holzkirchen, May 15, 2015 </strong>- More than 19,000 Novartis associates worldwide volunteer for local causes on Community Partnership Day</p><p>Novartis associates across 55 countries engaged in local volunteer efforts to support their communities in celebration of the company's annual Community Partnership Day (CPD).</p><p>May 8th of this year marked the 18th Community Partnership Day, commemorating the 1996 creation of Novartis as a global leader in healthcare.</p><p>There is strong participation from all Novartis divisions in 2014, including Sandoz. Here we feature some ...</p> May 15, 2014 13031 Sandoz launches AirFluSal? Forspiro? in South Korea http://www.alloftv.com/news/media-releases/sandoz-launches-airflusalr-forspiror-south-korea <p><strong>Seoul, May 14 2014 - </strong>Sandoz Korea announces that it is launching today AirFluSal? Forspiro?, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).</p><p>?The product was first approved in Denmark in December, 2013 with subsequent approvals in Germany, Belgium, Sweden, Norway, Hungary, Romania, Bulgaria and South Korea.</p><p>“We are pleased to launch AirFluSal? Forspiro? in South Korea. This is a milestone in our strategy of bringing our world class innovative inhaler to patients in Korea,” said Sujun Park, Country Head of ...</p> May 14, 2014 13026 Court supports access to Sandoz’s innovative respiratory device in Norway http://www.alloftv.com/news/media-releases/court-supports-access-sandozs-innovative-respiratory-device-norway <p>We are pleased that a court in Norway has denied GSK’s request to restrict access to Sandoz’s AirFluSal? Forspiro? in Norway. AirFluSal? Forspiro? provides patients with asthma and/or COPD with an award-winning innovative device for delivering the proven combination of salmeterol (a long-acting inhaled ?2-agonist) and fluticasone (an inhaled corticosteroid). We look forward to continuing to provide patients access to this important device. The decision is still subject to appeal.</p><p><strong>About Sandoz</strong></p><p>Sandoz, the generic pharmaceuticals division of Novartis, is a global ...</p> May 08, 2014 13021 Sandoz recognizes World Asthma Day 2014 http://www.alloftv.com/news/media-releases/sandoz-recognizes-world-asthma-day-2014 <p>Today Sandoz recognizes World Asthma Day. World Asthma Day is an annual event organized by the Global Initiative for Asthma (GINA) with the goal of improving asthma awareness and care around the world. This year’s theme is, “It’s time to control asthma.”</p><p>A chronic, inflammatory lung disease, asthma is currently the most common non-communicable disease amongst children worldwide. GINA estimates that there are 300 million sufferers worldwide and there may be an additional 100 million people living with asthma by 2025.</p><p>Asthma is characterized by airway obstruction which results in ...</p> May 06, 2014 13016 Sandoz launches generic version of Differin? Gel, 0.3% http://www.alloftv.com/news/media-releases/sandoz-launches-generic-version-differinr-gel-03 <p><strong>Princeton, New Jersey, April 28, 2014 - </strong>Sandoz today announced the US market introduction of its adapalene 0.3% gel, a generic version of Galderma Laboratories’ Differin? Gel, 0.3%.</p><p>Adapalene gel is a retinoid, indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. Acne vulgaris is a condition that affects nearly 85% of the US population at some point in their life.<sup>1</sup></p><p>"Sandoz is proud to market a high-quality, affordable generic version of this important topical therapy,” said Peter Goldschmidt, President of Sandoz ...</p> Apr 28, 2014 13011 Sandoz achieves important milestones on Phase III trials for key biosimilars programs http://www.alloftv.com/news/media-releases/sandoz-achieves-important-milestones-phase-iii-trials-key-biosimilars-programs <p><strong>April 28, 2014 - </strong>Sandoz continues to advance its industry-leading biosimilars pipeline that currently has six molecules in the Phase III clinical trial/filing prep phase.</p><p>As part of the Novartis Q1 announcements, Sandoz announced the following biosimilar development milestones:</p><ul><li>Sandoz completed the patient enrollment for its Phase III trial with biosimilar etanercept (Amgen's Enbrel?). The global clinical trial seeks to confirm biosimilarity with regard to safety, efficacy and immunogenicity of the Sandoz product versus Enbrel in patients with moderate to ...</li></ul> Apr 28, 2014 13006 Novartis announces Q1 2014 results http://www.alloftv.com/news/media-releases/novartis-announces-q1-2014-results <p><strong>Basel, April 24, 2014 - </strong>Novartis delivered solid sales and profit growth in the first quarter of 2014; strong innovation reinforces growth prospects as company transforms portfolio</p><p></p><div class="media-youtube-video media-element file-default media-youtube-2"><iframe class="media-youtube-player" width="740" height="447" title="Key product launches in Q1 2014" src="https://www.youtube.com/embed/mc7HVMMiTQs?wmode=opaque&amp;controls=" name="Key product launches in Q1 2014" frameborder="0" allowfullscreen="" id="Key product launches in Q1 2014">Video of Key product ...</iframe></div> Apr 24, 2014 13001 Sandoz joins forces with United Nations to combat a leading cause of child mortality worldwide http://www.alloftv.com/news/media-releases/sandoz-joins-forces-united-nations-combat-leading-cause-child-mortality <ul><li>Sandoz makes long-term commitment to support UN initiative on child mortality</li><li>Commitment to UN Every Newborn Action Plan involves development and supply of recommended WHO formulation for treating childhood pneumonia</li><li>Pneumonia is the leading cause of death globally among children under five</li></ul><p><strong>Holzkirchen, June 30, 2014 - </strong>Sandoz today announces a long-term commitment to help prevent the deaths of millions of children worldwide by supplying a key antibiotic formulation, as part of the United Nations’ new Every Newborn Action Plan.</p><p>The ...</p> Jun 30, 2014 12981 Sandoz recognized for its corporate responsibility and diversity & inclusion efforts http://www.alloftv.com/news/media-releases/sandoz-recognized-its-corporate-responsibility-and-diversity-inclusion-efforts <p><strong>February 17, 2014</strong> - Sandoz has been recognized by various organizations for its achievements in creating an inclusive workplace.</p><p></p><div class="media-youtube-video media-element file-default media-youtube-4"> ...</div> Feb 17, 2014 12946 New data demonstrates Sandoz' etanercept and rituximab biosimilar candidates bioequivalent to originator products http://www.alloftv.com/news/media-releases/new-data-demonstrates-sandoz-etanercept-and-rituximab-biosimilar-candidates <ul><li><p>Sandoz’ biosimilar etanercept candidate shows pharmacokinetic (PK) bioequivalence with no clinically meaningful differences in safety, tolerability and immunogenicity to the originator.<sup>1</sup></p></li><li><p>Sandoz’ biosimilar rituximab candidate shows PK bioequivalence and similar pharmacodynamics (PD), safety, efficacy and immunogenicity.<sup>2</sup></p></li><li><p>Biosimilar etanercept candidate is under regulatory review by EMA* and FDA** and biosimilar rituximab candidate is undergoing EMA review.</p></li></ul><p><strong>Holzkirchen, June 9, 2016</strong>?– Sandoz, a ...</p> Jun 09, 2016 12936 Tuberculosis remains a global health challenge; Sandoz continues commitment to fighting the disease http://www.alloftv.com/news/media-releases/tuberculosis-remains-global-health-challenge-sandoz-continues-commitment <p><strong>March 21, 2014 - </strong>Despite great progress made in the fight to eradicate Tuberculosis (TB), the disease remains a global killer and disproportionately affects the world’s poor. Sandoz, a leading provider of high-quality, affordable generic medicines, has the opportunity to significantly contribute to the fight against TB.</p><p>Tuberculosis (TB) is second only to HIV/AIDS as the greatest killer worldwide due to a single infectious agent, according to the World Health Organization. In 2012, 8.6 million people fell ill with TB and 1.3 million died from TB.</p><p><strong> ...</strong></p> Mar 21, 2014 12926 Sandoz' biosimilar rituximab regulatory submission accepted by European Medicines Agency http://www.alloftv.com/news/media-releases/sandoz-biosimilar-rituximab-regulatory-submission-accepted-european-medicines <ul><li><p>Sandoz advances biosimilar portfolio with sixth major biosimilar file acceptance in less than one year</p></li><li><p>Sandoz is seeking approval for all indications included in the reference product’s label</p></li><li><p>Sandoz’ submission includes data from multiple clinical trials with over 800 patients</p></li></ul><p><strong>Holzkirchen, 24 May, 2016</strong>?– Sandoz, a Novartis division and the global leader in biosimilars, announced today that the European Medicines Agency has accepted their Marketing Authorization Application for a biosimilar to Roche’s EU-licensed ...</p> May 24, 2016 12921 Belgium approves Sandoz’s Airflusal? Forspiro? http://www.alloftv.com/news/media-releases/belgium-approves-sandozs-airflusalr-forspiror <p><strong>Holzkirchen, Germany, February 12, 2014</strong> -?Sandoz announced it has received marketing authorization in Belgium for AirFluSal? Forspiro?, an innovative new inhaler for patients with asthma and COPD.</p><p>The product was first approved in Denmark on December 18th, 2013 with subsequent marketing authorizations received in Germany, Sweden, Hungary, Romania, Bulgaria, and Norway.</p><p>The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.</p><p>Belgium has ...</p> Feb 12, 2014 12906 Ecuador earthquake recovery: Sandoz announces financial support and product donation http://www.alloftv.com/news/media-releases/ecuador-earthquake-recovery-sandoz-announces-financial-support-and-product <p><strong>Holzkirchen, May 23, 2016 - </strong>In the wake of the earthquake that devastated northwest Ecuador in April, Sandoz, a Novartis division, today announced that it will support the recovery effort with financial aid and a product donation.</p><p>Hundreds of people lost their lives in the earthquake, which injured thousands more, devastated communities and left approximately 25,000 people living in shelters.</p><p>Employees locally have already been actively involved in a variety of relief operations, including preparing emergency kits of food and hygiene items for delivery to the ...</p> May 23, 2016 12901 Sandoz expands Tuberculosis activities in Africa http://www.alloftv.com/news/media-releases/sandoz-expands-tuberculosis-activities-africa <p><strong>March 19, 2014 - </strong>The Sandoz Tuberculosis (TB) program is increasing its reach in Africa. Sandoz is expanding its Tuberculosis portfolio as well as its Corporate Responsibility initiatives to support positive health outcomes for more patients and ultimately, contribute towards the eradication of the disease.</p><p><strong>Sandoz contributes to fighting Tuberculosis in Egypt</strong></p><p>In Egypt, TB constitutes the second most important public health problem, after schistosomiasis. Although Egypt has relatively low levels of TB according to data from the World Health ...</p> Mar 07, 2014 12896 Sandoz contributes to fighting the number one cause of death globally http://www.alloftv.com/news/media-releases/sandoz-contributes-fighting-number-one-cause-death-globally <p><strong>September 29, 2014 –</strong>?Today is World Heart Day. Cardiovascular disease (CVD) is a global burden accounting for 17.3 million deaths a year - significantly more than all deaths related to malaria, HIV and tuberculosis. By 2030, the World Health Organization estimates more than 23 million people annually will die of CVD.</p><p>Due to the prevalence of CVD globally, affordable medicines are a top concern for governments and health authorities. Sandoz has a broad portfolio of generic cardiovascular medications which prevent cardiovascular diseases by lowering lipid levels and ...</p> Sep 29, 2014 12886 Norway approves Sandoz’s Airflusal? Forspiro? http://www.alloftv.com/news/media-releases/norway-approves-sandozs-airflusalr-forspiror <p><strong>Holzkirchen, Germany, February 10, 2014</strong> -?Sandoz announced today it has received Norwegian marketing authorization for AirFluSal? Forspiro?, an innovative new inhaler for patients with asthma and COPD.</p><p>The product was first approved in Denmark on December 18th, 2013, with subsequent approvals in Germany, Sweden, Hungary, Romania and Bulgaria.</p><p>The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.</p><p>Norway has approved the 50/250μg and 50/ ...</p> Feb 10, 2014 12876 Sandoz continues women leadership program to build talent pipeline http://www.alloftv.com/news/media-releases/sandoz-continues-women-leadership-program-build-talent-pipeline <p><strong>Holzkirchen, Germany, September 26, 2014</strong> –?For the fourth consecutive year, Sandoz held the global?Women@Sandoz?leadership program for top women associates. Eighteen women, representing all Sandoz regions and functions, participated in the three-day event, sponsored by Sandoz Global Head, Richard Francis.</p><p>?</p><p>“We are focused on achieving and maintaining a strong gender balance at all levels, in every area of our business, because we believe diversity is good for business and inclusion is good for our people,” said Lisa Richert, Sandoz Chair of the Global ...</p> Sep 26, 2014 12866 Sandoz launches Kerdyn TM (tavaborole) topical solution, 5% from Anacor Pharmaceuticals, Inc. http://www.alloftv.com/news/media-releases/sandoz-launches-kerdyn-tm-tavaborole-topical-solution-5-anacor-pharmaceuticals <p><strong>Princeton, New Jersey, September 22, 2014</strong> -?Sandoz, through its branded dermatology business, PharmaDerm, today announced the US launch of KERYDINTM?(tavaborole) topical solution, 5%, developed ?by Anacor Pharmaceuticals, Inc.</p><p>In July 2014, Sandoz announced an agreement with Anacor Pharmaceuticals, Inc. to obtain exclusive rights to commercialize KERYDINTM in the US.</p><p>KERYDINTM?is the first oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to?Trichophyton rubrum or Trichophyton mentagrophytes, a fungal infection of the ...</p> Sep 23, 2014 12856 Sandoz launches the first generic version of Hectorol? http://www.alloftv.com/news/media-releases/sandoz-launches-first-generic-version-hectorolr <p><strong>Princeton, New Jersey, February 5, 2014</strong>?- Sandoz today announced the US launch of doxercalciferol injection vials, the first generic version of Genzyme's Hectorol?.</p><p>Doxercalciferol injection vials are indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.<sup>1</sup></p><p>"Sandoz is pleased to be the first company to market a high quality, affordable generic version of this important product to dialysis patients in the US," said Peter Goldschmidt, President of Sandoz Inc.</p><p>Sandoz is marketing ...</p> Feb 05, 2014 12851 Bulgaria approves Sandoz’s Airflusal? Forspiro? http://www.alloftv.com/news/media-releases/bulgaria-approves-sandozs-airflusalr-forspiror <p><strong>Holzkirchen, Germany, February 4, 2014</strong>?- Sandoz announced today it has received Bulgarian marketing authorization for AirFluSal? Forspiro?, an innovative new inhaler for patients with asthma and COPD.</p><p>The product was first approved in Denmark on December 18th, 2013. The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.</p><p>In January, 2014 Sandoz also received marketing authorizations for AirFluSal? Forspiro? in Germany, Sweden, Hungary and ...</p> Feb 04, 2014 12846 Generic medicines saved US healthcare system nearly USD 240 billion in 2013 http://www.alloftv.com/news/media-releases/generic-medicines-saved-us-healthcare-system-nearly-usd-240-billion-2013 <p><strong>September 18, 2014 </strong>- The use of generic medicines saved US patients and payors a total of USD 239 billion in 2013 – an increase of 14% over 2012 and more than in any previous year.</p><p>That was the main finding of a?<a href="http://www.gphaonline.org/media/cms/GPhA_Savings_Report.9.10.14_FINAL.pdf" target="_blank">new study</a>?by the IMS Institute for Healthcare Informatics, commissioned by the US Generic Pharmaceutical Association (GPhA).</p><p>The latest study, details of which have just been released by GPhA, showed that the use of generics in the US saved a total of ...</p> Sep 18, 2014 12841 Sandoz's Carol Lynch, Global Head Biopharmaceuticals is recognized in a Top 100 list, as the eighth most influential individual in medicine making http://www.alloftv.com/news/media-releases/sandozs-carol-lynch-global-head-biopharmaceuticals-recognized-top-100-list <p><strong>Holzkirchen, 29 April, 2016 - </strong>Sandoz’s Carol Lynch, Global Head Biopharmaceuticals, has been named as one of the most influential people involved in bringing medicines to patients by?<em>Medicine Maker</em>?– a leading international publication focused on drug development. Lynch was recognized as the eighth most influential in a Top 100 list that includes some of the most prominent and inspirational individuals involved in medicine making today.</p><p>Nominations were proposed by the publication’s readers and ranked by an expert judging panel. Individuals in the Top 100 ...</p> Apr 29, 2016 12836 Sandoz recognizes World Cancer Day 2014 http://www.alloftv.com/news/media-releases/sandoz-recognizes-world-cancer-day-2014 <p><strong>February 4, 2014</strong> -?Today Sandoz recognizes World Cancer Day. Cancer is a leading cause of death worldwide, accounting for 7.6 million deaths (around 13% of all deaths) in 2008, according to the World Health Organization. Deaths from cancer worldwide are projected to continue rising, with an estimated 13.1 million deaths in 2030.</p><p>The high cost of treating cancer can be a significant barrier to patients. Well over half of all cancer deaths (70%) in 2008 occurred in low- and middle-income countries, according to the World Health Organization. Sandoz oncology injectables ...</p> Feb 04, 2014 12831 Dealing with the spread of chronic disease in Africa http://www.alloftv.com/news/media-releases/dealing-spread-chronic-disease-africa <p><strong>September 10, 2014</strong> -?Sub-Saharan Africa is facing a healthcare tipping point. Policy and resources are mainly dedicated to fighting infectious diseases today. HIV, malaria and tuberculosis are the big targets. But over the next 15 years chronic diseases like cancer, heart disease, and kidney failure will become the major killers. By 2030 they will account for 42% of all deaths in the region, up from 25% today, says the World Health Organization.</p><p>?</p><p>Their rise may be inevitable, but their impact could be better managed. Education, policy and health investment can ...</p> Sep 10, 2014 12826 Sandoz supports prudent use of antibiotics on EU Antibiotic Awareness Day http://www.alloftv.com/news/media-releases/sandoz-supports-prudent-use-antibiotics-eu-antibiotic-awareness-day <p><strong>November 18, 2014</strong>?- European Antibiotic Awareness Day is an annual European public health initiative to raise awareness about the threat to public health of antibiotic resistance and the importance of prudent antibiotic use.</p><p>The latest data confirms that across the European Union the number of patients infected by resistant bacteria is increasing and that antibiotic resistance is a major threat to public health.</p><p>Prudent use of antibiotics can help stop resistant bacteria from developing and help keep antibiotics effective for the use of future generations.</p> ... Nov 18, 2014 12821 Sandoz sponsors diabetes awareness training for healthcare professionals in Ethiopia http://www.alloftv.com/news/media-releases/sandoz-sponsors-diabetes-awareness-training-healthcare-professionals-ethiopia <p><strong>November 14, 2014 -?</strong>Today is World Diabetes Day. Globally, 382 million people were living with diabetes in 2013. In 2035, it is estimated that 592 million people will be living with diabetes, a 55% increase from today<sup>1</sup>.</p><p>In sub-Saharan Africa, non-communicable diseases like diabetes are on the rise<sup>2</sup>. However, many African countries are ill-prepared to deal with these new healthcare challenges<sup>2</sup>.</p><p>In Ethiopia, Sandoz has initiated a new project called Sandoz Executive Medical Management Academy (SEMMA), an educational program for ...</p> Nov 14, 2014 12816 Sandoz launches ready-to-use oral formulation of ACC? cough medicine in Ukraine http://www.alloftv.com/news/media-releases/sandoz-launches-ready-use-oral-formulation-accr-cough-medicine-ukraine <ul><li>Sandoz launches new ready to use oral formulation of ACC? in the Ukrainian market</li><li>ACC? oral solution is used for children from 2 years old</li><li>New form has cherry flavor and is available with convenient dispenser</li></ul><p><strong>Kiev, November 12, 2014 –</strong>?Sandoz, the generic pharmaceutical division of Novartis, today announces the launch in Ukraine of a new ready-to-use oral formulation of ACC? cough medicine.</p><p>ACC? oral solution (active substance acetylcysteine) is used to treat acute and chronic bronchopulmonary diseases when it is necessary to reduce ...</p> Nov 12, 2014 12811 Novartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growth http://www.alloftv.com/news/media-releases/novartis-delivered-solid-q1-despite-gleevec-loss-exclusivity-investing-behind <ul><li><strong>Net sales up 1% (cc[1]), as Growth Products offset?<em>Gleevec</em>?impact</strong><ul><li><p>Growth Products[2] grew 24% (USD) to USD 3.9 billion, or 34% of Group net sales</p></li><li><p><em>Cosentyx</em>?(USD 176 million) continues to grow strongly, benefitting from long-term efficacy data for psoriasis and new launches in AS and PsA[3]</p></li><li><p><em>Entresto</em>?(USD 17 million) launch continues to accelerate in EU, field force ramping up in US</p></li></ul></li><li><strong>Core</strong><strong><sup>[1]</sup> operating income declines (-5% cc), driven by generic ...</strong></li></ul> Apr 21, 2016 12806 Sandoz Regional BioCamp winner finishes among top three in Basel http://www.alloftv.com/news/media-releases/sandoz-regional-biocamp-winner-finishes-among-top-three-basel <p><strong>Basel, September 2, 2014</strong> -?Janko Ignjatovic of Serbia has been selected as one of three individual winners of the Novartis International BioCamp held in Basel last week. Mr. Ignjatovic, who studies pharmacy at the University of Belgrade, came to the event through the Regional BioCamp, which took place in June and was organized by Lek, a Sandoz company.</p><p>?</p><p>Mr. Ignjatovic proved to be the best at combining a scientific and business solution in his case study at the Regional BioCamp in Slovenia, which is what promoted him to participate in the Novartis BioCamp. ...</p> Sep 01, 2014 12801 Sandoz recognizes World Pneumonia Day, raising awareness of the leading cause of infectious death globally among children under five http://www.alloftv.com/news/media-releases/sandoz-recognizes-world-pneumonia-day-raising-awareness-leading-cause-infectious <p style="list-style-type: none;">Pneumonia kills 1 million children each year. Amoxicillin is the #1 treatment for childhood pneumonia. Sandoz holds the leading position in antibiotics and amoxicillin is one of our top ten products worldwide.</p><p style="list-style-type: none;"><img alt="world-pneumonia-day" title="World Pneumonia Day" height="334" width="500" style="width: 100%; height: 100%;" class="media-element file-default" src="http://www.alloftv.com/sites/www.alloftv.com/files/n_prod_1274495.jpg" /></p><p style="list-style-type: none;">In June 2014, Sandoz committed to the world’s ...</p> Nov 12, 2014 12796 South Korea approves AirFluSal? Forspiro? http://www.alloftv.com/news/media-releases/south-korea-approves-airflusalr-forspiror <p><strong>Munich, Germany, February 28, 2014 - </strong>Sandoz announced today it has received South Korean marketing authorization for AirFluSal? Forspiro?, an innovative new inhaler for patients with asthma and COPD, marking its first approval in Asia.</p><p>The product was first approved in Denmark on December 18th, 2013, with subsequent approvals in Germany, Belgium, Sweden, Norway, Hungary, Romania and Bulgaria.</p><p>“We are pleased to receive the marketing authorization in South Korea for AirFluSal? Forspiro?. This is our first approval in Asia and outside Europe and a milestone in ...</p> Feb 28, 2014 12791 Sandoz’s Carol Lynch elected as chair of EGA’s European biosimilars group http://www.alloftv.com/news/media-releases/sandozs-carol-lynch-elected-chair-egas-european-biosimilars-group <p><strong>Holzkirchen, February 10, 2016</strong>?- Today, Sandoz announced that the European Generic Medicines Association (EGA) has elected Carol Lynch, Global Head Biopharmaceuticals &amp; Oncology Injectables, Sandoz as Chair of its European Biosimilars Group (EBG).</p><p>In this role Lynch, along with fellow EBG members, will support the expansion of patient access to high-quality biosimilar medicines, while ensuring the sustainability of the industry. Lynch believes that the industry’s areas of focus, under her tenure, for the next two years should be:?</p><ul><li>Increasing ...</li></ul> Feb 09, 2016 12786 Romania approves Sandoz’s Airflusal? Forspiro? http://www.alloftv.com/news/media-releases/romania-approves-sandozs-airflusalr-forspiror <p><strong>Holzkirchen, Germany, January 29, 2014</strong>?- Sandoz announced today it has received Romanian marketing authorization for AirFluSal? Forspiro?, an innovative new inhaler for patients with asthma and COPD.</p><p>The product was first approved in Denmark on December 18th, 2013. The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.</p><p>Earlier this month, Sandoz also received marketing authorizations for AirFluSal? Forspiro? in Germany, Sweden and Hungary. ...</p> Jan 29, 2014 12781 Sandoz receives EC approval for subcutaneous route of administration in biosimilar Binocrit's? nephrology indication http://www.alloftv.com/news/media-releases/sandoz-receives-ec-approval-subcutaneous-route-administration-biosimilar <ul><li><p>Sandoz’ epoetin alfa product offering has already generated more than 400,000<sup>1</sup>?patient years of experience worldwide</p></li><li><p>EC approval expands Sandoz biosimilar offering to the healthcare community</p></li></ul><p><strong>Holzkirchen, 08 April, 2016</strong>?– Sandoz, a Novartis division and the global leader in biosimilars, announced today that the European Commission (EC) has approved a type II variation for the addition of a subcutaneous (s.c.) route of administration in Binocrit’s<sup>?</sup>?(epoetin alfa) nephrology indication*.</p><p>“By expanding our ...</p> Apr 08, 2016 12771 Novartis delivered strong sales growth and core margin expansion in 2015; announces plans to accelerate growth at Alcon, streamline Group operations http://www.alloftv.com/news/media-releases/novartis-delivered-strong-sales-growth-and-core-margin-expansion-2015-announces <p><strong>Basel, January 27, 2016</strong> - Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations</p><ul><li><strong>Strong growth (cc) in full year sales, core operating income and core EPS[2]</strong><ul><li>Net sales up 5% (cc) and core operating income up 10% (cc)</li><li>Core operating income margin up 1.3 percentage points (cc)</li><li>Operating income (-2% cc) down mainly due to amortization of the new oncology assets</li><li>Net income (-18% cc) impacted by exceptional gains in ...</li></ul></li></ul> Jan 27, 2016 12766 Sandoz donates 25,000 units of benzathine penicillin to rheumatic heart disease study in Zambia http://www.alloftv.com/news/media-releases/sandoz-donates-25000-units-benzathine-penicillin-rheumatic-heart-disease-study-0 <p><strong>August 29, 2014 -?</strong>Life-saving medicines from Sandoz have arrived at the University Teaching Hospital in Lusaka, Zambia. The donated units of benzathine penicillin will support a new rheumatic heart disease study by the Novartis Institutes for BioMedical Research (NIBR). Penicillin prophylaxis is the only way by which new cases of rheumatic heart disease can be prevented.<br /><a href="http://www.alloftv.com/news/media-releases/sandoz-donates-25000-units-benzathine-penicillin-rheumatic-heart-disease-study">Read more</a>.</p> Aug 29, 2014 12761 Sandoz donates 25,000 units of benzathine penicillin to rheumatic heart disease study in Zambia http://www.alloftv.com/news/media-releases/sandoz-donates-25000-units-benzathine-penicillin-rheumatic-heart-disease-study <p><strong>August 21, 2014</strong> –?Life-saving medicines from Sandoz have arrived at the University Teaching Hospital in Lusaka, Zambia. The donated units of benzathine penicillin will support a new rheumatic heart disease study by the Novartis Institutes for BioMedical Research (NIBR). Penicillin prophylaxis is the only way by which new cases of rheumatic heart disease can be prevented.</p><p>Rheumatic heart disease (RHD) has been practically eradicated in wealthy nations, but in the developing world the disease remains a major cause of morbidity and mortality, particularly in children ...</p> Aug 21, 2014 12756 Sandoz licenses its biosimilar rituximab to Kyowa Hakko Kirin in Japan http://www.alloftv.com/news/media-releases/sandoz-licenses-its-biosimilar-rituximab-kyowa-hakko-kirin-japan <p><strong>Holzkirchen, 25 January, 2016</strong>?– Sandoz, a Novartis company and the global leader in biosimilars, announced today that it has entered into an exclusive license agreement with Kyowa Hakko Kirin Co., Ltd for the distribution and promotion of its biosimilar rituximab - a monoclonal antibody, in Japan.</p><p>Under the terms of the agreement, Sandoz will file for marketing authorization of biosimilar rituximab and its manufacture if approved. Kyowa Hakko Kirin will be responsible for all sales, marketing and promotion activities in Japan.</p><p>Kyowa Hakko Kirin will pay Sandoz ...</p> Jan 25, 2016 12751 Novartis publishes updated 2015 segment financials reflecting new division structure http://www.alloftv.com/news/media-releases/novartis-publishes-updated-2015-segment-financials-reflecting-new-division <ul><li><p>Updated segment financials reflect transfer of Ophthalmic Pharmaceuticals franchise from Alcon to Pharmaceuticals, and 19 mature products from Pharmaceuticals to Sandoz, as outlined in Q4 and FY 2015 earnings release</p></li><li><p>No change in audited 2015 Consolidated Financial Statements for the total Group</p></li></ul><p><strong>Basel, March 31, 2016</strong>?– Novartis announced today that it has published updated 2015 quarterly and full year segment financials reflecting the new division structure, as announced in the January 27, 2016 earnings release, as if the transfers ...</p> Mar 31, 2016 12741 Novartis announces Q4/Full Year 2013 results http://www.alloftv.com/news/media-releases/novartis-announces-q4full-year-2013-results <p><strong>Basel, January 29, 2014</strong>?- Novartis delivers strong sales and innovation in 2013; underlying business performance reinforces growth prospects.</p><p><a href="https://www.novartis.com/sites/www.novartis.com/files/q4-2013-media-release_en.pdf" target="_blank">Read the media release</a></p><p></p><div class="media-youtube-video media-element file-default media-youtube-5"> ...</div> Jan 29, 2014 12736 Novartis moves to address superbug threat http://www.alloftv.com/news/media-releases/novartis-moves-address-superbug-threat <p><em><strong>Rex Clements</strong>, Head of Business Unit Anti-Infectives &amp; API comments on the antimicrobial resistance declaration:</em></p><p></p><div class="media media-element-container media-default"><audio controls="controls"><source src="http://www.alloftv.com/sites/www.alloftv.com/files/2016-01-21-novartis-antimicrobial-resistance.mp3" type="audio/mpeg"></source></audio><br /><div class="field field-name-filename-field field-type-text field-label-hidden"><div class="field-items"><div class="field-item even"><div>Listen to the audio (1:23 min).mp3</div></div></div></div></div> ... Jan 21, 2016 12731 Sandoz launches first generic version of cyclophosphamide injection, USP http://www.alloftv.com/news/media-releases/sandoz-launches-first-generic-version-cyclophosphamide-injection-usp <p><strong>Princeton, New Jersey, November 10, 2014 –</strong>?Sandoz today announced the US market introduction of cyclophosphamide injection, USP.</p><p>Sandoz is launching cyclophosphamide injection, USP, through collaboration with Jiangsu Hengrui Medicine Co., the owner of the product’s Abbreviated New Drug Application (ANDA).</p><p>Cyclophosphamide for injection, USP, is a chemotherapy agent used to treat certain types of cancer in adults and pediatric patients. It is also used in selected cases of biopsy proven “minimal change” nephrotic syndrome in children. New cases of leukemia, ...</p> Nov 10, 2014 12726 Sandoz receives approvals in Baltics for innovative respiratory inhaler AirFluSal? Forspiro? http://www.alloftv.com/news/media-releases/sandoz-receives-approvals-baltics-innovative-respiratory-inhaler-airflusalr <ul><li>Regulatory authorities in Estonia, Latvia and Lithuania grant marketing authorizations for AirFluSal? Forspiro?</li><li>Approval for 50-250 and 50-500μg dosage forms</li><li>AirFluSal Forspiro already launched in four European countries and South Korea</li></ul><p><strong>Holzkirchen, November 4, 2014 –</strong>?Sandoz announces today that the pharmaceutical regulatory authorities in Estonia, Latvia and Lithuania have all granted marketing authorizations for AirFluSal? Forspiro?, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD). ...</p> Nov 05, 2014 12721 Novartis releases 2013 Corporate Responsibility Performance Report http://www.alloftv.com/news/media-releases/novartis-releases-2013-corporate-responsibility-performance-report <p><strong>August 29, 2014 -?</strong>Novartis has a strong history of CR activities, and transparent reporting is a central part of our commitment to corporate responsibility. We have publicly reported on our performance in this area since 2000 through our Annual Report and several online and printed materials.</p><p>For 2013, we have consolidated information previously published in our separate GRI; Health, Safety and Environment; and United Nations Global Compact reports into a single Corporate Responsibility Performance Report.</p><p>This report enhances our transparency in several key ...</p> Aug 29, 2014 12716 Sandoz Brazil introduces a new option for oncology patients http://www.alloftv.com/news/media-releases/sandoz-brazil-introduces-new-option-oncology-patients <ul><li>First generic version of oncology medicine bortezomibe in Brazil</li><li>New therapeutic option for patients suffering from multiple myeloma</li></ul><p><strong>S?o Paulo, August 26, 2014</strong> -?Sandoz, the generic pharmaceutical division of Novartis, today announces the market introduction in Brazil of the first generic version of oncology medicine bortezomibe.</p><p>Sandoz will distribute and promote bortezomibe in Brazil, based on an agreement with Accord Pharmaceuticals. This will be the first Sandoz medicine marketed in Brazil for treatment of hematologic – as opposed to ...</p> Aug 26, 2014 12706 New research highlights need for a competitive functioning biologics market to achieve full potential of biosimilars for patients, healthcare professionals and payors http://www.alloftv.com/news/media-releases/new-research-highlights-need-competitive-functioning-biologics-market-achieve <p>New research published today in a report from the IMS Institute for Healthcare Informatics -?<em>Delivering on the Potential of Biosimilar Medicines: The Role of Functioning Competitive Markets</em>, highlights the opportunity for biosimilars to create savings of approx USD 110 billion for health systems across Europe and the U.S over the next five years. The report highlights that the extent to which biosimilars will provide these forecasted savings will depend on the policy and implementation approaches adopted by country healthcare systems.</p><p>The report, funded by Novartis, will ...</p> Mar 29, 2016 12701 Sandoz advances its biosimilars program with European Medicines Agency (EMA) acceptance of regulatory submission for biosimilar etanercept http://www.alloftv.com/news/media-releases/sandoz-advances-its-biosimilars-program-european-medicines-agency-ema-acceptance <ul><li>Sandoz is seeking approval for all indications included in the reference product’s label which includes chronic inflammatory conditions like rheumatoid arthritis and psoriasis.</li><li>Sandoz believes that the totality of evidence in its submission, including two pivotal clinical studies, will demonstrate that the biosimilar etanercept is highly similar to the reference product.</li><li>EMA acceptance follows recent FDA regulatory submission acceptance and is the third of ten regulatory filings planned over a three year period (2015-2017).</li></ul><p><strong>Holzkirchen, 8 December, ...</strong></p> Dec 08, 2015 12696 EGA becomes Medicines for Europe http://www.alloftv.com/news/media-releases/ega-becomes-medicines-europe <p>Medicines for Europe is the new name of EGA (European Generic and Biosimilar Medicines Association) as of today. Representing the pharmaceutical companies supplying the largest share of medicines across Europe, Medicines for Europe is the voice of the generic, biosimilar and value added medicines industries in Europe and a leading partner providing better health and better access to all European patients.</p><p><a href="http://www.medicinesforeurope.com/news/ega-becomes-medicines-for-europe/" target="_blank">Read the media release</a></p> Mar 10, 2016 12691 Phase III data shows Sandoz’ proposed biosimilar pegfilgrastim has similar safety and efficacy as the reference product http://www.alloftv.com/news/media-releases/phase-iii-data-shows-sandoz-proposed-biosimilar-pegfilgrastim-has-similar-safety <ul><li>PROTECT 2 study compared safety and efficacy of the proposed biosimilar pegfilgrastim with the reference product for the prevention of neutropenia in patients with breast cancer.</li><li>The study met its primary endpoints demonstrating equivalence and non-inferiority to the reference product.</li><li>Data presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition.</li></ul><p><strong>Holzkirchen, 7 December 2015</strong>?– Sandoz, a Novartis company and global leader in biosimilars, today announced results from the PROTECT 2 study which compared the ...</p> Dec 07, 2015 12686 Sandoz proud to announce first Novartis Access treatments to Kenya http://www.alloftv.com/news/media-releases/sandoz-proud-announce-first-novartis-access-treatments-kenya <ul><li><p>Novartis Access is a first-of-its-kind portfolio of products aimed at increasing access to medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer in low- and low-middle-income countries</p></li><li><p>First Novartis Access shipment delivered to Kenya where almost 30% of people die from NCDs every year</p></li></ul><p><strong>Holzkirchen, World Child Cancer Day (March 1, 2016):</strong>?Sandoz is pleased to announce that the first Novartis Access shipment has just been delivered to Kenya. This shipment includes medicines against cardiovascular ...</p> Mar 01, 2016 12681 Sandoz receives positive CHMP opinion for s.c. route of administration in biosimilar Binocrit's? nephrology indication http://www.alloftv.com/news/media-releases/sandoz-receives-positive-chmp-opinion-sc-route-administration-biosimilar <p><strong>Holzkirchen, 25 February, 2016 </strong>– Sandoz, a Novartis company and the global leader in biosimilars, announced today that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a type II variation for the addition of a subcutaneous (s.c.) route of administration in Binocrit’s? (epoetin alfa) nephrology indication*.</p><p>“Today’s CHMP positive opinion brings us one step closer to strengthening our epoetin alfa product offering which has already generated more than 400,000<sup>1</sup>?patient years of experience worldwide” said Carol Lynch, ...</p> Feb 15, 2016 12671 Sandoz recognizes International Women's Day, highlighting importance of healthcare access for women globally http://www.alloftv.com/news/media-releases/sandoz-recognizes-international-womens-day-highlighting-importance-healthcare <p><strong>March 7, 2014</strong></p><p>Today Sandoz recognizes International Women’s Day (IWD), a globally-recognized day which celebrates the economic, social and cultural contributions made by women.</p><p>It is observed each year on March 8th. The United Nations theme for IWD this year is?<a href="http://www.un.org/en/events/womensday/" target="_blank">“Equality for Women is Progress for All.”</a></p><p> ...</p> Feb 26, 2014 12666 Sandoz launches Zarxio? (filgrastim-sndz), the first biosimilar in the United States http://www.alloftv.com/news/media-releases/sandoz-launches-zarxiotm-filgrastim-sndz-first-biosimilar-united-states <p><strong>Holzkirchen, September 3, 2015</strong>?– Sandoz, a Novartis company, announced today that Zarxio<sup>TM</sup>?(filgrastim-sndz) is now available in the United States. Zarxio is the first biosimilar approved by the US Food and Drug Administration (FDA) and the first to launch in the US.</p><p>“As the pioneer and global leader in biosimilars, Sandoz has maintained a commitment to bringing high-quality biosimilar medicines to patients and healthcare professionals around the world,” said Richard Francis, Global Head, Sandoz. “With the launch of Zarxio, we look forward to increasing ...</p> Sep 03, 2015 12656 Sandoz receives first aproval in Latin America for innovative respiratory inhaler Airflusal? Forspiro? http://www.alloftv.com/news/media-releases/sandoz-receives-first-aproval-latin-america-innovative-respiratory-inhaler <ul><li>Mexico’s Health Authority (COFEPRIS) grants marketing authorization for Airflusal? Forspiro?</li><li>Approval for 50-100mg, 50-250mg and 50-500mg dosage forms</li><li>Product to be branded IrFlosolTM?Forspiro? in Mexico</li><li>Airflusal? Forspiro? already launched in four European countries as well as in South Korea</li></ul><p><strong>Holzkirchen, August 20, 2014</strong> –?Sandoz announces today that the Mexican Health Authority (COFEPRIS) has granted Sandoz marketing authorization for Airflusal? Forspiro?, an innovative new inhaler for patients with asthma and/or chronic ...</p> Aug 19, 2014 12651 Sandoz launches generic version of Pulmicort Respules? http://www.alloftv.com/news/media-releases/sandoz-launches-generic-version-pulmicort-respulesr <p><strong>Princeton, New Jersey, July 28, 2015</strong>– Sandoz today announced the US market introduction of its budesonide inhalation suspension, a generic version of Pulmicort Respules? (budesonide) inhalation suspension 1 mg strength by AstraZeneca LP.</p><p>Sandoz’s budesonide inhalation suspension product is indicated for maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age. Budesonide inhalation suspension is not indicated for the relief of acute bronchospasm.</p><p>"Asthma is unfortunately becoming increasingly prevalent while few ...</p> Jul 28, 2015 12646 RAND projects $44.2 billion reduction in U.S. spend on biologics over the next decade from introduction of biosimilars http://www.alloftv.com/news/media-releases/rand-projects-442-billion-reduction-us-spend-biologics-over-next-decade <p style="list-style-type: none;"><strong style="list-style-type: none;">November 03, 2014 -?</strong>Today the RAND Corporation projected that the introduction of biosimilar drugs in the US will reduce direct spending on biologics by USD 44.2 billion from 2014 to 2024. Currently there are no biosimilars approved by the FDA for use in the US. Products submitted for review by FDA through the Biologics Price Competition and Innovation Act pathway are developed with highly similar quality, safety and efficacy to marketed biologics, but they come at a lower price. A biosimilar will be approved if ...</p> Nov 04, 2014 12641 Sandoz comments on the FDA’s proposed rule for Designation of Official Names and Proper Names for Certain Biological Products http://www.alloftv.com/news/media-releases/sandoz-comments-fdas-proposed-rule-designation-official-names-and-proper-names <p>The Novartis Group of companies, recently provided comments on the U.S. Food and Drug Administration (FDA) Proposed Rule entitled “Designation of Official Names and Proper Names for Certain Biological Products”.</p><p>As the first company to market a biosimilar in the US, Sandoz, a Novartis company, shares the FDA’s commitment to patient safety and to ensuring accurate perceptions of the safety and effectiveness of biological products.</p><p>Sandoz believes biosimilars and interchangeable biologics should share the same non-proprietary name as their respective reference products and that ...</p> Nov 19, 2015 12636 Hungary approves Sandoz’s Airflusal? Forspiro? http://www.alloftv.com/news/media-releases/hungary-approves-sandozs-airflusalr-forspiror <p><strong>Holzkirchen, Germany, January 16, 2014</strong>?- Sandoz announced it has received marketing authorization in Hungary for AirFluSal? Forspiro?, an innovative new inhaler for patients with asthma and COPD.</p><p>The product was first approved in Denmark on December 18th, 2013 with subsequent marketing authorizations received earlier this week also in Germany and Sweden.</p><p>The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.</p><p>Hungary has approved the 50- ...</p> Jan 16, 2014 12631 Sandoz launches Breathe Africa program to improve asthma diagnosis, treatment and patient outcomes in Zambia http://www.alloftv.com/news/media-releases/sandoz-launches-breathe-africa-program-improve-asthma-diagnosis-treatment-and <ul><li>Non-communicable diseases like asthma are rising rapidly in sub-Saharan Africa where healthcare systems are ill-prepared to cope1 – Zambia is ranked #1 in the world for mortality due to asthma<sup>2</sup></li><li>Increasing the medical expertise of local healthcare professionals is a quick and sustainable way to improve patient health outcomes<sup>3,4</sup></li><li>Sandoz is calling on European doctors with an interest in asthma to volunteer for Breathe Africa</li></ul><p><strong>Holzkirchen, July 24, 2015</strong>?– Sandoz today announced the launch of Breathe Africa, a respiratory ...</p> Jul 24, 2015 12626 Sandoz strengthens its biosimilars portfolio with acquisition of Pfizer's biosimilar infliximab in EEA http://www.alloftv.com/news/media-releases/sandoz-strengthens-its-biosimilars-portfolio-acquisition-pfizers-biosimilar <ul><li><p>Sandoz acquires rights to PF-06438179 (biosimilar infliximab) in the European Economic Area (EEA)*</p></li><li><p>Sandoz plans to complete Phase III development program and file for registration in the EU</p></li><li><p>Deal strengthens Novartis immunology portfolio which includes investigational biosimilars adalimumab, etanercept and rituximab</p></li></ul><p><strong>Holzkirchen, 12 February, 2016</strong>?– Sandoz, a Novartis company and a global leader in biosimilars, announced today that it has acquired from Pfizer the rights for the development and commercialization of PF- ...</p> Feb 12, 2016 12621 Novartis announces portfolio transformation, focusing company on leading businesses with innovation power and global scale: Pharmaceuticals, Eye Care and Generics http://www.alloftv.com/news/media-releases/novartis-announces-portfolio-transformation-focusing-company-leading-businesses <ul><li>Acquires GSK oncology products, strengthening Novartis' leading Oncology business with novel therapies and becomes GSK's preferred commercialization partner for its oncology pipeline</li><li>Combines Novartis OTC with GSK's consumer business in a joint venture, creating a world-leading consumer healthcare business and maintaining Novartis' presence in in this sector</li><li>Divests Vaccines business (excluding flu) to GSK, creating a global leader in vaccines</li><li>In a separate transaction, divests Novartis Animal Health to Lilly</li></ul><p><strong>Transactions improve Novartis' ...</strong></p> Apr 22, 2014 12616 Sandoz Germany launches innovative new topical therapy for erectile dysfunction, a leading urological disorder http://www.alloftv.com/news/media-releases/sandoz-germany-launches-innovative-new-topical-therapy-erectile-dysfunction <ul><li>Sandoz Germany launches Vitaros?, an innovative new patent-protected therapy for leading urology disorder erectile dysfunction (ED)</li><li>First topical therapy approved for treatment of ED, characterized by ease of use, rapid onset and high tolerability</li><li>Launch in Sandoz’s largest EU market further demonstrates company commitment to meeting unmet medical need across key therapeutic areas</li></ul><p><strong>Holzkirchen, August 18, 2014</strong> -?Sandoz, the generic pharmaceuticals division of Novartis, today announces the launch in Germany of Vitaros?, an innovative new ...</p> Aug 18, 2014 12606 Court ruling paves the way for launch of Sandoz’s Zarxio as first US biosimilar http://www.alloftv.com/news/media-releases/court-ruling-paves-way-launch-sandozs-zarxio-first-us-biosimilar <p><strong>Holzkirchen, Germany, July 22, 2015 -?</strong>The US Court of Appeals for the Federal Circuit issued a ruling on July 21 that paves the way for Sandoz to launch Zarxio (filgrastim) after September 2, as the first US biosimilar.</p><p>The court, which ruled following an appeal hearing on June 3, found that provision of the biosimilar application to the originator company within 20 days of filing – the so-called “patent dance” component of the US biosimilar approval pathway, or BPCIA -- is optional.</p><p>However, it also ruled that the required notice of commercial marketing can ...</p> Jul 22, 2015 12601 Sandoz continues to advance its biosimilars program: Regulatory submission for Sandoz’ proposed biosimilar pegfilgrastim accepted by the FDA http://www.alloftv.com/news/media-releases/sandoz-continues-advance-its-biosimilars-program-regulatory-submission-sandoz <ul><li>Sandoz demonstrates commitment to oncology by seeking approval for its proposed biosimilar pegfilgrastim.</li><li>Sandoz believes that the totality of evidence in its submission, including three pivotal clinical studies, will demonstrate that the proposed biosimilar is highly similar to the reference product.</li><li>Proposed biosimilar pegfilgrastim filing is the second of ten regulatory filings planned over the next three years.</li></ul><p><strong>Holzkirchen, November 18, 2015</strong>?– Sandoz, a Novartis company and the global leader in biosimilars, announced today that the US ...</p> Nov 18, 2015 12596 Novartis delivered solid performance in the second quarter, with strong innovation and progress on new launches http://www.alloftv.com/news/media-releases/novartis-delivered-solid-performance-second-quarter-strong-innovation-and <p><strong>Basel, July 21, 2015</strong>?- Commenting on the results, Joseph Jimenez, CEO of Novartis, said: "Novartis had a strong quarter for innovation, with US approval and launch of both Entresto and Glatopa being key highlights. Additionally, we reported a broad range of positive clinical data across franchises, including Tafinlar/Mekinist in metastatic melanoma and Cosentyx in ankylosing spondylitis. We are confident we will deliver on our priorities for the year, and confirm our full-year guidance."</p><ul><li><strong>Sales</strong>,<strong>?core[1] operating income and core EPS grew ...</strong></li></ul> Jul 21, 2015 12586 Sandoz Sweden launches innovative new topical therapy for erectile dysfunction,a leading urological disorder http://www.alloftv.com/news/media-releases/sandoz-sweden-launches-innovative-new-topical-therapy-erectile-dysfunctiona <ul><li>Sandoz Sweden launches Vitaros?, an innovative new patent-protected therapy for leading urology disorder erectile dysfunction (ED)</li><li>First topical therapy approved for treatment of ED, characterized by ease of use, rapid onset and high tolerability</li><li>Launch demonstrates Sandoz commitment to meeting unmet medical need across key therapeutic areas, including Women’s and Men’s Health</li></ul><p><strong>Holzkirchen, August 4, 2014</strong> -?Sandoz, the generic pharmaceuticals division of Novartis, today announces the launch in Sweden of Vitaros?, an innovative new topical ...</p> Aug 04, 2014 12581 Sandoz launches Airflusal ? Forspiro? in Denmark http://www.alloftv.com/news/media-releases/sandoz-launches-airflusal-r-forspiror-denmark <p><strong>Copenhagen, January 20, 2014</strong>?- Sandoz announces that it is launching in Denmark today AirFluSal? Forspiro?, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).</p><p>The product was first approved in Denmark on December 18th, 2013 with subsequent marketing authorizations received earlier this week also in Germany and Sweden.</p><p>Today’s launch in Denmark follows the announcement on December 18 that Sandoz had received its first EU market authorization for AirFluSal? Forspiro? after the completion the EU regulatory ...</p> Jan 20, 2014 12576 Sandoz launches the Balans programme in Central and Eastern Europe to promote healthier living http://www.alloftv.com/news/media-releases/sandoz-launches-balans-programme-central-and-eastern-europe-promote-healthier <ul><li>The Balans programme focuses on educating patients about the benefits of probiotics, which help our digestive tract to metabolize the food we consume, maintain the health of our intestines, and support the function of our immune system.</li><li>The use of probiotics presents a natural and safe way to keep the balance of our intestinal microbiota, which is important for our well-being.</li><li>The Balans programme complements the 30 years of experience Sandoz has in the field of microbiotics and its strong line of Linex probiotic products.</li></ul><p><strong>Holzkirchen, Germany, July ...</strong></p> Jul 09, 2015 12571 Sweden approves Sandoz’s Airflusal? Forspiro? http://www.alloftv.com/news/media-releases/sweden-approves-sandozs-airflusalr-forspiror <p><strong>Holzkirchen, Germany, January 14, 2014</strong>?- Sandoz announced today it has received Swedish marketing authorization for AirFluSal? Forspiro?, an innovative new inhaler for patients with asthma and COPD.</p><p>The product was first approved in Denmark on December 18th, 2013. The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device. On January 13, 2014 Sandoz also received marketing authorization for AirFluSal? Forspiro? in Germany.</p><p>Sweden has approved the ...</p> Jan 14, 2014 12566 Sandoz teams up with World Child Cancer to "even the odds" for children worldwide http://www.alloftv.com/news/media-releases/sandoz-teams-world-child-cancer-even-odds-children-worldwide <p><strong>Holzkirchen, February 15, 2016 - </strong>Sandoz, together with leading global charity World Child Cancer (WCC), is pleased to announce a new health initiative in the Philippines, aimed at improving the standard of care for children suffering from cancer.</p><p>Cancer survival rates for children in the Philippines are less than 20%, compared to an average of 80% in developed countries. The goal of the new partnership, further details of which will be announced next month, is to help “even the odds” by supporting the development of specialist treatment centers in the island region ...</p> Feb 12, 2016 12556 Novartis introduces Declaration for Patients http://www.alloftv.com/news/media-releases/novartis-introduces-declaration-patients <p>Sandoz is proud to be a part of the Novartis Declaration for Patients, which Novartis introduced today at the Innovating for Patients event in Basel, Switzerland. The patient declaration is a public commitment to patients around the world of what they can expect from us as a company. It clearly states our responsibilities and commitments to patients across five key areas, from clinical trials to access to our medicines.</p><p><a href="http://www.alloftv.com/sites/www.alloftv.com/files/novartis-declaration-infographic.pdf">Click here to read more about the Novartis Declaration for Patients ( ...</a></p> Jun 27, 2015 12551 Sandoz launches three new products in Japan http://www.alloftv.com/news/media-releases/sandoz-launches-three-new-products-japan <p><strong>Tokyo, June 25, 2015</strong>?– Sandoz has announced the Japanese market introduction of three new products including clopidogrel, tacrolimus and pitavastatin (line extension).</p><p>Clopidogrel, a generic version of Sanofi’s Plavix?, is used for suppression of recurrence of ischemic cerebrovascular disorder. Tacrolimus, a generic version of Astellas’s PROGRAF?, is used among others to prevent organ transplant rejection (kidney, liver, heart, lung, pancreas, small intestine). Pitavastatin, a generic version of Kowa’s LIVALO?, is used for lowering cholesterol.</p><p>“We are pleased ...</p> Jun 25, 2015 12546 Novartis announces completion of transactions with GSK http://www.alloftv.com/news/media-releases/novartis-announces-completion-transactions-gsk <ul><li>Completes transactions with GSK including: acquisition of GSK oncology portfolio, creation of Consumer Healthcare joint venture, and sale of non-influenza Vaccines business</li><li>Sharpens company focus on growing segments of innovative pharmaceuticals, eye care and generics</li><li>Addition of GSK oncology products and two pipeline compounds is expected to expand Novartis position in targeted therapies and small molecules, positioning Novartis as a preferred partner for combination agents</li><li>Transactions expected to immediately lift core margins and further support overall ...</li></ul> Mar 02, 2015 12541 Generic medicines saved US healthcare system more than USD 250 billion in 2014 alone http://www.alloftv.com/news/media-releases/generic-medicines-saved-us-healthcare-system-more-usd-250-billion-2014-alone <p>Generic medicines saved the US healthcare system a record USD 254 billion in 2014, according to a new report compiled by the IMS Institute for Healthcare Informatics on behalf of the US Generic Pharmaceutical Association (GPhA).</p><p>Chip Davis, President and CEO of the GPhA, said: “The facts are irrefutable, generic drugs drive enormous health care savings.</p><p>“This new report reinforces that generic drugs are a critical part of any solution to rising costs for patients, payors and the entire healthcare system. Safe, effective and more affordable generic medicines mean increased ...</p> Nov 05, 2015 12536 Novartis releases 2014 Corporate Responsibility Performance Report http://www.alloftv.com/news/media-releases/novartis-releases-2014-corporate-responsibility-performance-report <p><strong>June 24, 2015</strong>?- Novartis has a strong history of CR activities, and transparent reporting is a central part of our commitment to corporate responsibility. We have publicly reported on our performance in this area since 2000 through our Annual Report and several online and printed materials.</p><p>The 2014 CR Performance Report aims to meet the needs and expectations of CR professional audiences by offering easy access to key data. The report also details progress against Novartis priorities, defined following a CR materiality process.</p><p>In response to feedback received ...</p> Jun 24, 2015 12531 Sandoz announces training program for midwives in Ethiopia, to reduce maternal and newborn mortality http://www.alloftv.com/news/media-releases/sandoz-announces-training-program-midwives-ethiopia-reduce-maternal-and-newborn <ul><li>Approximately 400 mothers and newborns die in Ethiopia each day<sup>1,2?</sup>partly due to health workers’ limited knowledge in the area of obstetrics</li><li>Enhancing medical knowledge and skills of health workers helps reduce maternal and newborn mortality</li><li>Sandoz is committed to increasing access to high-quality, affordable medicines, as well as healthcare services and education for mothers and children</li></ul><p><strong>Holzkirchen, Germany, March 2, 2015?</strong>– Sandoz today announced the launch of a new program, New Life &amp; New Hope, to improve maternal and ...</p> Mar 02, 2015 12526 Novartis delivered solid sales growth with strong margin expansion and major innovation in the third quarter http://www.alloftv.com/news/media-releases/novartis-delivered-solid-sales-growth-strong-margin-expansion-and-major <p><strong>Basel, October 28, 2014 -</strong>?Commenting on the results, Joseph Jimenez, CEO of Novartis, said: "Novartis delivered a very strong third quarter. We delivered solid sales growth with margin expansion. At the same time, we reached key innovation milestones, particularly with LCZ696 in heart failure and AIN457 in psoriasis, underlining the innovation power of the company."</p><ul><li><strong>Net sales up 4% (+5% cc)<sup>1</sup>?in Q3, with operating margin increase across Q3 and 9M</strong><ul><li>Net sales of USD 14.7 billion grew 4% (+5% cc<sup>2</sup>) in Q3</li><li>Strong ...</li></ul></li></ul> Oct 28, 2014 12516 Sandoz announces US launch of Glatopa(TM), the first generic competitor to Copaxone? 20mg http://www.alloftv.com/news/media-releases/sandoz-announces-us-launch-glatopatm-first-generic-competitor-copaxoner-20mg <ul><li>Glatopa is the first FDA-approved, substitutable generic version of Copaxone? 20mg, a treatment for relapsing forms of multiple sclerosis</li><li>Sandoz has begun shipping to US customers following recent FDA approval</li><li>Novartis and Sandoz are driving access to a full range of differentiated, high-quality MS therapeutic options, complemented by a full range of support services</li></ul><p><strong>Holzkirchen, Germany, June 18, 2015?</strong>- Sandoz, a Novartis company, today announced the US launch of GlatopaTM, the first generic version of Teva's Copaxone? (glatiramer acetate ...</p> Jun 18, 2015 12511 Novartis highlights strong innovation momentum at its second Meet Novartis Management investor day http://www.alloftv.com/news/media-releases/novartis-highlights-strong-innovation-momentum-its-second-meet-novartis <ul><li><strong>Strong progress on innovation across divisions</strong><ul><li>Pharmaceuticals is building breadth and depth in seven franchises, including Oncology, where it is complementing leadership in targeted therapies and CART with immuno-oncology assets</li><li>Alcon is focused on eye care innovation, including strengthening its IOL pipeline over prior year and focusing on early-stage discovery in Ophthalmic Pharmaceuticals</li><li>Sandoz is extending its lead in differentiated generics, exemplified by first-of-a-kind FDA approvals for biosimilar Zarxio and generic Copaxone? 20mg ...</li></ul></li></ul> Jun 18, 2015 12501 On World Cancer Day, Sandoz highlights global problem of child cancer http://www.alloftv.com/news/media-releases/world-cancer-day-sandoz-highlights-global-problem-child-cancer <p><strong>February 04, 2015?-?</strong>Between 160,000 and 200,000 children are estimated to be diagnosed with childhood cancer and around 100,000 die from it each year. With proper diagnosis, treatment and drugs, most childhood cancers can be cured. In the developed countries, 80% of children survive, which is a great achievement in oncology treatment. However, in middle and low income countries, survival is estimated to drop to as low as 5%. Cancer is a leading cause of childhood deaths in these countries. This disparity is primarily because of lack of proper diagnosis and basic treatment ...</p> Feb 04, 2015 12496 Novartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full - year guidance http://www.alloftv.com/news/media-releases/novartis-delivered-strong-core-margin-expansion-cc-and-continued-strengthen <p><strong>Basel, October 27, 2015</strong>?- Commenting on the results, Joseph Jimenez, CEO of Novartis, said: “Novartis continued to make strong progress on innovation and key launches in the third quarter. The Pharmaceuticals and Sandoz Divisions continue to perform exceptionally well, offsetting softness in the Alcon Division. Entresto was approved and launched in the US, and Tafinlar + Mekinist was approved in the EU for BRAF-mutant melanoma. We confirm our full - year guidance.”</p><ul><li><strong>Solid growth (cc[1]) in Q3 sales, core operating income, core EPS for continuing ...</strong></li></ul> Oct 27, 2015 12491 FDA accepts Sandoz application biosimilar filgrastim http://www.alloftv.com/news/media-releases/fda-accepts-sandoz-application-biosimilar-filgrastim <ul><li>Sandoz is the first company to announce it has filed for approval of a biologic under the biosimilars pathway created in the Biologics Price Competition and Innovation Act of 2009 (BPCIA)</li><li>FDA’s acceptance of Sandoz’s filing is an important first step in increasing US patient access to affordable, high-quality biologics</li><li>Sandoz is a global leader in biosimilars with over 50% share of the global biosimilars market1</li></ul><p><strong>Holzkirchen, July 24, 2014</strong> –?Sandoz, a Novartis Group company, announced today that the US Food and Drug Administration (FDA) has ...</p> Jul 24, 2014 12481 Novartis delivered solid sales growth, margin expansion and pipeline progress in 2014; portfolio transformation will focus company on leading businesses http://www.alloftv.com/news/media-releases/novartis-delivered-solid-sales-growth-margin-expansion-and-pipeline-progress <p><strong>Basel, January 27, 2015?</strong>- Commenting on the results, Joseph Jimenez, CEO of Novartis, said: "2014 was a transformational year for Novartis. We improved our execution, while taking steps to focus the company on our three leading businesses with global scale. We delivered solid sales growth with margin expansion, strengthened innovation, and advanced our quality and productivity agendas. I'm confident that we are positioned for future success."</p><ul><li><strong>Net sales grew in FY 2014, with strong core[1] margin expansion</strong><ul><li>Net sales increased 1% (+3% cc[1 ...</li></ul></li></ul> Jan 27, 2015 12476 Sandoz introduces authorized generic version of LESCOL? XL in the US http://www.alloftv.com/news/media-releases/sandoz-introduces-authorized-generic-version-lescolr-xl-us <p><strong>Princeton, New Jersey, October 16, 2015</strong>?–?Sandoz today announced the US introduction of fluvastatin sodium extended-release tablets, USP, an authorized generic version (AGx) of LESCOL? XL, which is marketed by Novartis Pharmaceuticals Corporation. This is another great example of cross-divisional collaboration in the context of the ongoing Novartis Group Rx-Gx program.</p><p>Fluvastatin sodium extended-release tablets, USP are indicated as an adjunctive therapy with changes to diet to lower cholesterol, slow the progression of heart disease and reduce the risk of needing ...</p> Oct 19, 2015 12471 Sandoz biosimilar filgrastim recommended for approval by FDA Oncologic Drugs Advisory Committee http://www.alloftv.com/news/media-releases/sandoz-biosimilar-filgrastim-recommended-approval-fda-oncologic-drugs-advisory-0 <ul><li>Oncologic Drugs Advisory Committee (ODAC) votes in favor of recommending biosimilar filgrastim for approval in the US</li><li>Biosimilar filgrastim recommended to be approved for use in all requested indications</li><li>Committee’s recommendation based on review of extensive data from analytical, non-clinical, clinical studies and post-marketing pharmacovigilance</li></ul><p><strong>Holzkirchen, January 7, 2014?</strong>– Sandoz, a Novartis company, announced today that US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of its ...</p> Jan 07, 2014 12466 Sandoz launches generic version of INTUNIV? extended release tablets in the US http://www.alloftv.com/news/media-releases/sandoz-launches-generic-version-intunivr-extended-release-tablets-us <p><strong>Princeton, New Jersey</strong><strong>, June?4, 2015</strong>?– Sandoz today announced the US market introduction of guanfacine hydrochloride extended release tablets, a generic version of INTUNIV?, which is currently marketed by Shire Pharmaceuticals.</p><p>Guanfacine hydrochloride extended release is a central alpha2A-adrenergic receptor agonist indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications. Guanfacine is not a central nervous system (CNS) stimulant. The mechanism of action of ...</p> Jun 04, 2015 12461 Sandoz participates in development project: "Quality Assured Essential Medicines for Ghana" http://www.alloftv.com/news/media-releases/sandoz-participates-development-project-quality-assured-essential-medicines <p><strong>March 14, 2014 - </strong>Sandoz 1 A Pharma is pleased to participate in the develoPPP.de (DPP) project “Quality Assured Essential Medicines for Ghana,” a three-year development partnership aimed at increasing access to high-quality, affordable medicines for patients in Ghana.</p><p>The project will be led by the German International Cooperation Agency, Deutsche Gesellschaft fuer Internationale Zummenarbeit GmbH (GIZ) and financed by the German Federal Ministry for Economic Cooperation and Development (BMZ).</p><p>The DPP project will focus on increasing access to medicines ...</p> Feb 24, 2014 12451 Following commitment to United Nations’ Every Newborn Action Plan, Sandoz supplies life-saving antibiotic to combat child mortality http://www.alloftv.com/news/media-releases/following-commitment-united-nations-every-newborn-action-plan-sandoz-supplies <ul><li>Sandoz delivers 100,000 packs of amoxicillin 250mg dispersible tablets (DT) to UN and joins UN Pneumonia Innovations Team</li><li>Pneumonia is the leading cause of infectious death globally among children under five, killing 1 million children each year and amoxicillin is the #1 treatment for childhood pneumonia</li></ul><p><strong>Holzkirchen, October 23, 2014 –</strong>?Sandoz today announces the delivery of 100,000 packs of amoxicillin 250mg dispersible tablets (DT) to the United Nations (UN). This follows Sandoz’ commitment to the UN Every Newborn Action Plan, launched in June ...</p> Oct 23, 2014 12446 Sandoz launches authorized generic version of Vivelle-Dot? http://www.alloftv.com/news/media-releases/sandoz-launches-authorized-generic-version-vivelle-dotr <p><strong>Princeton, New Jersey, December 22, 2014?</strong>– Sandoz today announced the US market introduction of estradiol transdermal system, an authorized generic version of Vivelle-Dot?, which is marketed by Novartis Pharmaceuticals Corporation.</p><p>Estradiol transdermal system is indicated for treatment of certain menopausal symptoms and for the prevention of postmenopausal osteoporosis.</p><p>“We are pleased to partner with our colleagues at NPC to further expand our offering of affordable, high-quality medicines,” said Peter Goldschmidt, President of Sandoz Inc.</p><p>According to ...</p> Dec 22, 2014 12441 Germany approves Sandoz’s Airflusal? Forspiro? http://www.alloftv.com/news/media-releases/germany-approves-sandozs-airflusalr-forspiror <p><strong>Holzkirchen, Germany, January 13, 2014</strong>?- Sandoz announced today it has received German marketing authorization for AirFluSal? Forspiro?, an innovative new inhaler for patients with asthma and COPD.</p><p>The product was first approved in Denmark on December 18th, 2013. The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.</p><p>Germany has approved the 50-500 μg dosage form for the continuous treatment of patients above 12 years of age with persistent ...</p> Jan 13, 2014 12436 Kenya is first country to launch ‘Novartis Access’, expanding affordable treatment options against chronic diseases http://www.alloftv.com/news/media-releases/kenya-first-country-launch-novartis-access-expanding-affordable-treatment <ul><li>Novartis Access is a first-of-its-kind portfolio of products aimed at increasing access to medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer in low- and low-middle-income countries</li><li>Program supports Kenyan government on noncommunicable disease (NCD) prevention and control – by 2030, NCDs are expected to cause more than 60% of deaths in the country<sup>1</sup></li><li>Agreements signed with Kenyan government and NGOs include programs to distribute medicines, raise disease awareness and strengthen healthcare system capabilities in key ...</li></ul> Oct 15, 2015 12431 Sandoz receives first approval for Airflusal? Forspiro? http://www.alloftv.com/news/media-releases/sandoz-receives-first-approval-airflusalr-forspiror <p><strong>Munich, December 18, 2013</strong>?- Sandoz announced today that it has received Danish marketing authorization for AirFluSal? Forspiro?, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD). The Danish approval follows the completion of EU decentralized procedures (DCP) for eight EU countries, including Denmark.</p><ul><li>Novel inhaler approved for patients with asthma and COPD</li><li>Approval follows completion of EU decentralized procedure (DCP)</li><li>AirFluSal? Forspiro? strengthens Sandoz respiratory portfolio and ...</li></ul> Dec 18, 2013 12421 Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim http://www.alloftv.com/news/media-releases/sandoz-advances-its-biosimilars-program-ema-acceptance-regulatory-submission <ul><li><p>Sandoz’ late-stage biosimilar pipeline gains momentum with sustained investment - five of 10 planned regulatory filings achieved</p></li><li><p>Sandoz believes that the totality of evidence in its submission, including three pivotal clinical studies, demonstrates that the proposed biosimilar is highly similar to the reference product.</p></li><li><p>Sandoz is the European market leader in both the daily G-CSF class and for biosimilar filgrastim.</p></li></ul><p><strong>Holzkirchen, 11 February, 2016</strong>?– Sandoz, a Novartis company and the global leader in biosimilars, ...</p> Feb 11, 2016 12416 Sandoz Brazil launches Tadalafil, first generic version of Cialis? to treat erectile dysfunction http://www.alloftv.com/news/media-releases/sandoz-brazil-launches-tadalafil-first-generic-version-cialisr-treat-erectile <ul><li>Licensing agreement with Eli Lilly enables Sandoz to commercialize and distribute Cialis? in the Brazilian market</li></ul><p><strong>Sao Paulo, December 18, 2014</strong>?– Sandoz, the generics pharmaceutical division of Novartis, announces today that it is launching Tadalafil, a generic version of Cialis?, indicated to treat patients with erectile dysfunction. With the launch, Sandoz will be the first pharmaceutical company to market a generic version of Cialis? in Brazil.</p><p>Tadalafil is the result of a trade agreement with Eli Lilly Brazil?, which allows Sandoz to commercialize ...</p> Dec 18, 2014 12411 Sandoz obtains rights in US to commercialize Kerydintm (Tavaborole) topical solution, 5% from Anacor Pharmaceuticals, INC. http://www.alloftv.com/news/media-releases/sandoz-obtains-rights-us-commercialize-kerydintm-tavaborole-topical-solution-5 <p><strong>Princeton, New Jersey, July 21, 2014</strong> -?Sandoz today announced an agreement with Anacor Pharmaceuticals, Inc. to obtain exclusive rights to commercialize Anacor’s drug KERYDINTM?(tavaborole) topical solution, 5% in the US, through its branded dermatology business, PharmaDerm.</p><p>Two weeks ago Anacor announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application for KERYDINTM, the first oxaborole antifungal approved for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes, a fungal ...</p> Jul 21, 2014 12406 Sandoz is a triple winner at 2015 Global Generics & Biosimilars Awards in Madrid http://www.alloftv.com/news/media-releases/sandoz-triple-winner-2015-global-generics-biosimilars-awards-madrid <p><strong>Holzkirchen, October 14, 2015</strong>?- Last night in Madrid, Sandoz picked-up three accolades at the?<em>Global Generics &amp; Biosimilars Awards</em>?hosted by the?<em>Generics Bulletin</em>?including?<em>Company of the Year</em>.</p><p>The recent launch of Zarxio, the first US biosimilar, which has paved the way for greater access to high-quality biologics won?<em>Biosimilar Initiative of the Year</em>. In September this year, Sandoz became the first company to introduce a biosimilar in the US – leading the way in the US just as it did in Europe nearly 10 years ago.</p><p>The ...</p> Oct 14, 2015 12401 Recognizing rural women: New global reports confirm importance of midwifery for maternal health in challenged areas http://www.alloftv.com/news/media-releases/recognizing-rural-women-new-global-reports-confirm-importance-midwifery-maternal <p style="list-style-type: none;"><strong style="list-style-type: none;">October 15, 2014?-</strong>?Today is International Day of Rural Women, established by the United Nations to bring awareness to the critical contribution rural women make to improving living conditions worldwide. For rural women, health issues such as pregnancy complications are significantly compounded by limited availability of knowledgeable medical staff. Two new global reports confirm the vital role midwives can play in dramatically reducing maternal and newborn death.</p><p style="list-style-type: none;"> ...</p> Oct 15, 2014 12396 Sandoz Poland celebrates the opening of a new packaging plant in Stryków http://www.alloftv.com/news/media-releases/sandoz-poland-celebrates-opening-new-packaging-plant-strykow <p><strong>Stryków, May 07, 2015</strong>?– Sandoz, the generic Division of Novartis is announcing today the opening of the Sandoz Packaging Centre in Stryków – a project valued at 171 million PLN. It is one of the largest investment projects in the Polish pharmaceutical sector completed in recent years. Thanks to the expansion of the existing plant in Stryków, 90 new jobs have been created to date, soon to be followed by at least 40 additional ones. The opening ceremony was attended by government officials, including Deputy Prime Minister Janusz Piechociński, local politicians, members of ...</p> May 07, 2015 12391 Novartis Africa Day highlights company’s efforts to expand access to healthcare http://www.alloftv.com/news/media-releases/novartis-africa-day-highlights-companys-efforts-expand-access-healthcare <p><strong>Basel, December 05, 2014 - </strong>Today, Novartis senior executives gather in Basel, Switzerland for the first-ever Novartis Africa Day, to review the company’s innovative work in Africa, including growing commercial activity, novel approaches to expand access to high-quality, affordable medicines, local talent development and the company’s Malaria Initiative.</p><ul><li>Africa’s healthcare challenges are compounded as it begins to face a dual disease burden as non-communicable diseases rise</li><li>In addition to existing corporate responsibility efforts such as its Malaria ...</li></ul> Dec 05, 2014 12376 Novartis publishes Corporate Responsibility Overview http://www.alloftv.com/news/media-releases/novartis-publishes-corporate-responsibility-overview <p>Januar 08, 2014 -?Novartis recently published a comprehensive overview of its Corporate Responsibility strategy and programs.</p><p><a href="http://www.alloftv.com/sites/www.alloftv.com/files/novartis-cr-overview.pdf" target="_blank">Learn more (PDF 743 KB)</a></p> Jan 08, 2014 12366 Today is International Day of People with Disabilities http://www.alloftv.com/news/media-releases/today-international-day-people-disabilities <p><strong>December 03, 2014</strong>?- Established in 1992, International Day of People with Disabilities is a United Nations sanctioned day that aims to promote an understanding of people with disabilities and encourage support for their dignity, rights and well-being.</p><p>People with disabilities often face barriers, including physical, social, economic, educational, attitudinal and health care barriers. There are many types of disabilities and impairments, both visible and invisible.</p><p>More than 1 billion people live with a disability, says the world report on disability, published ...</p> Dec 03, 2014 12361 Sandoz Brazil creates program to support employment for persons with disabilities http://www.alloftv.com/news/media-releases/sandoz-brazil-creates-program-support-employment-persons-disabilities <p><strong>December 03, 2014</strong>?- Sandoz in Brazil has partnered with the Londrina Ministry of Labor, the Londrina State University and other local entities to create INcluir, a unique program that offers professional skills training to people with disabilities. The aim of the program is to build-up the regional talent pool of qualified, disabled workers and to support their employment.</p><p></p><div class="media media-element-container media-default media-align-center"> ...</div> Dec 03, 2014 12356 Novartis maintained strong innovation momentum in second quarter, while reconfirming full year outlook http://www.alloftv.com/news/media-releases/novartis-maintained-strong-innovation-momentum-second-quarter-while-reconfirming <p><strong>Basel, July 17, 2014 -?</strong>Commenting on the results, Joseph Jimenez, CEO of Novartis, said: "Novartis delivered solid financial performance with core margin expansion in the second quarter and first half. Pharmaceuticals, in particular, showed improved productivity, driving core operating leverage for the Group. We also made significant progress on innovation across the portfolio, reaching milestones such as FDA approval for Zykadia in ALK+ non-small cell lung cancer, FDA Fast Track designation and rolling submission for LCZ696 in chronic heart failure, CHMP recommendation ...</p> Jul 14, 2014 12351 Novartis delivered sales growth (cc), significant margin expansion(cc) and strong innovation in Q1; now with a more focused portfolio http://www.alloftv.com/news/media-releases/novartis-delivered-sales-growth-cc-significant-margin-expansioncc-and-strong <p><strong>Basel, April 23, 2015?</strong>- Commenting on the results, Joseph Jimenez, CEO of Novartis, said: "Our focus on execution has resulted in a strong operational performance. We have completed the GSK and Lilly transactions and innovation continues to be strong. We had three approvals in Oncology, FDA priority review for LCZ696, Zarxio became the first biosimilar approved under the new pathway in the US and we launched Cosentyx globally. We are on track to deliver our full-year guidance."</p><p>?</p><ul><li><strong>Continuing operations<sup>1</sup>?saw sales, core<sup>2</sup>? ...</strong></li></ul> Apr 23, 2015 12341 Sandoz wins Generics Bulletin 'Biosimilars Initiative of the Year' award http://www.alloftv.com/news/media-releases/sandoz-wins-generics-bulletin-biosimilars-initiative-year-award <p><strong>Holzkirchen, October 13, 2014 -</strong>?Sandoz is pleased to announce that Generics Bulletin, a newsletter covering commercial and regulatory information for the global generics industry, has awarded the company with “Biosimilars Initiative of the Year”, for its file acceptance of G-CSF (filgrastim) in the US. Sandoz also achieved top-three podium positions in the Company of the Year; Company of the Year – Americas; and Innovation of the Year Awards categories.</p><p>On July 24, Sandoz, announced that the FDA accepted its application for filgrastim, making Sandoz the first company ...</p> Oct 13, 2014 12336 Sandoz launches biosimilar Filgrastim BS Injection 75 μg/150 μg/ 300 μg Syringe in Japan http://www.alloftv.com/news/media-releases/sandoz-launches-biosimilar-filgrastim-bs-injection-75-ug150-ug-300-ug-syringe <p><strong>Tokyo, Japan, December 1, 2014</strong>?― Sandoz, the generic pharmaceutical division of Novartis, today announced the launch in Japan of biosimilar Filgrastim BS Injection 75μg / 150μg / 300μg Syringe. Filgrastim is used with certain cancer patients to accelerate recovery of infection-fighting white blood cells after chemotherapy (prevention of neutropenia) and is also used to stimulate mobilization of hematopoietic stem cells for collection and transplantation.</p><p>“As the pioneer and global leader in biosimilars we are very pleased to announce the launch of our second ...</p> Dec 01, 2014 12331 FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept http://www.alloftv.com/news/media-releases/fda-accepts-sandoz-regulatory-submission-proposed-biosimilar-etanercept <ul><li>Etanercept is an anti-TNF medicine used to treat a range of immunological diseases including rheumatoid arthritis and psoriasis.</li><li>Sandoz is seeking approval for all indications included in the reference product’s label.</li><li>Sandoz believes that the totality of evidence in its submission, including two pivotal clinical studies, will demonstrate that the proposed biosimilar is essentially the same as the reference product.</li></ul><p><strong>Holzkirchen, October 2, 2015</strong>?– Sandoz, a Novartis company and the global leader in biosimilars, announced today that the US ...</p> Oct 02, 2015 12326 Sandoz receives FDA approval for Glatopa? as the first generic competitor to MS therapy Copaxone? 20mg http://www.alloftv.com/news/media-releases/sandoz-receives-fda-approval-glatopatm-first-generic-competitor-ms-therapy <ul><li>Glatopa is the first FDA-approved, substitutable generic version of Copaxone? 20mg, a treatment for relapsing forms of multiple sclerosis</li><li>Novartis and Sandoz are driving access to a full range of differentiated, high-quality MS therapeutic options, complemented by a full range of support services</li></ul><p><strong>Holzkirchen, Germany, April 16, 2015?</strong>– Sandoz, a Novartis company, today announced the US approval of GlatopaTM, the first generic version of Teva’s Copaxone? (glatiramer acetate injection) 20 mg/ml one-time-daily multiple sclerosis therapy.</p><p>“Sandoz ...</p> Apr 16, 2015 12321 Sandoz launches authorized generic version of Tobi? http://www.alloftv.com/news/media-releases/sandoz-launches-authorized-generic-version-tobir <p><strong>Princeton, New Jersey, July 14, 2014</strong> -?Sandoz today announced the US market introduction of tobramycin inhalation solution, USP, an authorized generic version of TOBI?, currently marketed by Novartis Pharmaceuticals Corporation<sup>1</sup>.</p><p>Tobramycin inhalation solution, USP is indicated for the management of cystic fibrosis patients whose lungs contain bacteria called P. aeruginosa.</p><p>Cystic fibrosis is a life-threatening genetic disease that primarily affects the lungs and digestive system. An estimated 30,000 children and adults in the United States (70,000 ...</p> Jul 15, 2014 12311 Innovative respiratory inhaler Airflusal? Forspiro? receives Alufoil Trophy 2015 http://www.alloftv.com/news/media-releases/innovative-respiratory-inhaler-airflusalr-forspiror-receives-alufoil-trophy-2015 <p><strong>April 16, 2015?</strong>- AirFluSal? Forspiro?, an innovative respiratory inhaler from Sandoz, has won the coveted Alufoil Trophy 2015 in the Product Preservation category. The inhaler uses a specially designed alufoil blister strip, which was developed by Amcor Flexibles, that ensures a longer shelf life of the inhalation powder.</p><p>This recognition for technical innovation is the second award for AirFluSal? Forspiro?. In 2011, the device received the Red Dot Product Design Award, an internationally recognized quality seal awarded by the Design Zentrum Nordrhein Westfalen in ...</p> Apr 16, 2015 12306 Sandoz supports HIV/AIDS awareness and increased access to treatment for this major global public health issue http://www.alloftv.com/news/media-releases/sandoz-supports-hivaids-awareness-and-increased-access-treatment-major-global <p><strong>December 01, 2014</strong>?- According to the?<a href="http://www.who.int/gho/hiv/en/" target="_blank">World Health Organization (WHO)</a>, Human Immunodeficiency Virus (HIV/AIDS) has caused the deaths of millions of people and is one of the most destructive pandemics in history. World AIDS Day, celebrated annually on December 1st, was established by the WHO in 1988 to raise awareness of the virus, which is preventable and treatable.</p><p>HIV attacks the body's immune system, the body's defense against diseases. HIV can be passed on through infected bodily fluids, most commonly ...</p> Dec 01, 2014 12301 Sandoz receives approval in Portugal for innovative respiratory inhaler AirFluSal? Forspiro? http://www.alloftv.com/news/media-releases/sandoz-receives-approval-portugal-innovative-respiratory-inhaler-airflusalr <ul><li>Portuguese Health Authority grants marketing authorization for AirFluSal? Forspiro?</li><li>Approval for 50-250 and 50-500μg dosage forms</li><li>AirFluSal Forspiro already launched in four European countries and South Korea</li></ul><p><strong>Holzkirchen, October 09, 2014 –</strong>?Sandoz announces today that the Portuguese Health Authority (Infarmed) has granted marketing authorization for AirFluSal? Forspiro?, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).</p><p>AirFluSal Forspiro has now been approved in a total of 10 ...</p> Oct 09, 2014 12296 Sandoz's Joerg Windisch reelected as chair of Ega’s European biosimilars group http://www.alloftv.com/news/media-releases/sandozs-joerg-windisch-reelected-chair-egas-european-biosimilars-group <p>Today, Sandoz announced that the European Generic medicines Agency (EGA) has reelected Dr. Joerg Windisch, Chief Science Officer at Sandoz, as chair of its European Biosimilars Group (EBG).</p><p><a href="http://www.sandoz-biosimilars.com/en/mediacenter/statement/140709en_Joerg_Windisch_Reelected_as_Chair_of_EGAs_European_Biosimilars_Group.shtml" target="_blank">Read more</a></p> Jul 09, 2014 12286 Sandoz launches authorized generic version of EXFORGE? in the US http://www.alloftv.com/news/media-releases/sandoz-launches-authorized-generic-version-exforger-us <p><strong>Princeton, New Jersey, March 31, 2015 –</strong>?Sandoz today announced the US market introduction of amlodipine and valsartan combination tablets, a generic version of EXFORGE? made by Novartis.</p><p>Amlodipine and valsartan tablets are a combination of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB), and valsartan, an angiotensin II receptor blocker (ARB).</p><p>Amlodipine and valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure:</p><ul><li>in patients not adequately controlled on monotherapy with a DHP CCB or an ARB</li><li> ...</li></ul> Mar 31, 2015 12281 World Heart Day 2015: Joining forces to fight the #1 cause of death worldwide http://www.alloftv.com/news/media-releases/world-heart-day-2015-joining-forces-fight-1-cause-death-worldwide <p><strong>September 29, 2015</strong>?– An estimated 17.3 million people die of cardiovascular diseases?<a href="http://www.who.int/cardiovascular_diseases/publications/atlas_cvd/en/" target="_blank">every year</a>. That makes it the number one cause of death in the world today, with 80% of those deaths occurring in low- and middle-income countries. Ischemic heart disease (e.g. heart attacks) is responsible for 7.3 million of total CVD deaths and cerebrovascular disease (e.g. strokes) for a further 6.2 million.</p><h2><strong>The big causes of cardiovascular disease</strong></h2><p>The ...</p> Sep 29, 2015 12276 Sandoz receives approvals in Ireland and Czech Republic for innovative respiratory inhaler AirFluSal? Forspiro? http://www.alloftv.com/news/media-releases/sandoz-receives-approvals-ireland-and-czech-republic-innovative-respiratory <ul><li>Regulatory authorities in Ireland and Czech Republic grant marketing authorizations for AirFluSal? Forspiro?</li><li>Approval for 50-250 and 50-500μg dosage forms</li><li>AirFluSal Forspiro already launched in four European countries and South Korea</li></ul><p><strong>Holzkirchen, November 19, 2014?</strong>– Sandoz announces today that the pharmaceutical regulatory authorities in Ireland and the Czech Republic have granted marketing authorizations for AirFluSal? Forspiro?, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).</p><p> ...</p> Nov 19, 2014 12271 Sandoz receives approvals in Ireland and Sandoz launches innovative respiratory inhaler AirFluSal?? Forspiro?? in Portugal and Ireland http://www.alloftv.com/news/media-releases/sandoz-receives-approvals-ireland-and-sandoz-launches-innovative-respiratory <ul><li>Sandoz launches 50-250 and 50-500μg dosage forms in Portugal and Ireland</li><li>Innovative inhaler offers asthma and COPD patients a new therapeutic option</li><li>Now available to patients in 14 countries, as global roll-out continues apace</li></ul><p><strong>Holzkirchen, March 11, 2015</strong>?– Sandoz today announces the launch of AirFluSal<sup>?</sup>?Forspiro<sup>?</sup>, an innovative inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD), in Portugal and Ireland.</p><p>AirFluSal, which was first approved in Denmark, has now been launched in a ...</p> Mar 11, 2015 12266 Sandoz partners with WHO-CC to bring pharmacovigilance training to Ghana http://www.alloftv.com/news/media-releases/sandoz-partners-who-cc-bring-pharmacovigilance-training-ghana <p><strong>Holzkirchen, Germany, February 24, 2014 - </strong>Sandoz in Ghana recently partnered with the World Health Organization Collaboration Centre (WHO-CC) for Advocacy and Training in Pharmacovigilance to provide Ghanaian pharmacists with advanced training.</p><p>The WHO Centre aims to improve and promote patient safety by driving the rational use of medicines through training healthcare professionals in pharmacovigilance. The recent training took place at the Korle-Bu Teaching Hospital, the biggest teaching hospital of Ghana.</p><p>The thirty pharmacists attending the event received ...</p> Feb 24, 2014 12261 Sandoz commits to providing affordable, quality eye care on World Sight Day http://www.alloftv.com/news/media-releases/sandoz-commits-providing-affordable-quality-eye-care-world-sight-day <p><strong>October 9, 2014 –</strong>?Approximately 285 million people worldwide live with low vision and blindness, according to the World Health Organization. Of these, 39 million people are blind and 246 million have moderate or severe visual impairment. Often a result of poor living conditions, 90% of blind people live in low-income countries.</p><p></p><div class="media media-element-container media-default left-offset"> ...</div> Oct 09, 2014 12256 Phase III data shows Sandoz’ investigational biosimilar filgrastim has similar safety and efficacy as Amgen’s NEUPOGEN? http://www.alloftv.com/news/media-releases/phase-iii-data-shows-sandoz-investigational-biosimilar-filgrastim-has-similar <ul><li>Pivotal PIONEER study compared safety and efficacy of the two compounds in the prevention of neutropenia in patients with breast cancer</li><li>PIONEER data supported filing for biosimilar filgrastim in the US</li><li>The abstract of the study results is published online as part of the 56th American Society of Hematology (ASH) Annual Meeting and Exposition</li></ul><p><strong>Holzkirchen,?</strong><strong>December 8</strong><strong>, 2014</strong>?– Sandoz, a Novartis company, announced today Phase III data that demonstrated similarity of its investigational biosimilar filgrastim ...</p> Dec 08, 2014 12251 Novartis launches ‘Novartis Access’, a portfolio of affordable medicines to treat chronic diseases in lower-income countries http://www.alloftv.com/news/media-releases/novartis-launches-novartis-access-portfolio-affordable-medicines-treat-chronic <ul><li>First-of-its-kind portfolio approach in healthcare industry, aiming to increase availability and affordability of 15 medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer</li><li>Novartis portfolio to be offered to governments and non-governmental organizations in low- and low-middle-income countries for USD 1 per treatment, per month</li><li>Some 28 million people die from chronic diseases in low- and middle-income countries each year, representing 75% of such deaths globally<sup>1</sup></li></ul><p><strong>New York, September 24, 2015 ...</strong></p> Sep 24, 2015 12241 FDA approves first biosimilar Zarxio? (filgrastim-sndz) from Sandoz http://www.alloftv.com/news/media-releases/fda-approves-first-biosimilar-zarxiotm-filgrastim-sndz-sandoz <ul><li>Sandoz is the first company to receive approval of a biosimilar in the US through the new FDA biosimilars pathway established under BPCIA</li><li>Zarxio is approved for all indications included in the reference product’s (NEUPOGEN?) label</li><li>Approval paves way for greater access to high-quality biologics in the US and underscores Sandoz global leadership in biosimilars</li></ul><p><strong>Holzkirchen, March 06, 2015 –</strong>?Sandoz, a Novartis company, announced today that the US Food and Drug Administration (FDA) approved Zarxio<sup>TM?</sup>(filgrastim-sndz) for all ...</p> Mar 06, 2015 12236 Sandoz launches authorized generic version of Diovan? in the US http://www.alloftv.com/news/media-releases/sandoz-launches-authorized-generic-version-diovanr-us <p><strong>Princeton, New Jersey, July 8, 2014</strong> -?Sandoz today announced the US introduction of an authorized generic version of Diovan? (valsartan) tablets for the treatment of high blood pressure (HBP).</p><p>?This launch follows the Sandoz US introduction of an authorized generic version of Diovan HCT? (valsartan and hydrochlorothiazide) in 2012. Both Diovan and Diovan HCT are marketed in the US by Novartis Pharmaceuticals Corporation (NPC) and are indicated for the treatment of HBP, a condition that affects approximately one in three US adults.1,2</p><p>“We are pleased to offer ...</p> Jul 08, 2014 12231 Sandoz commits to increasing patient access to important respiratory treatments http://www.alloftv.com/news/media-releases/sandoz-commits-increasing-patient-access-important-respiratory-treatments <p><strong>November 19, 2014</strong>?- Today, on World Chronic Obstructive Pulmonary Disease (COPD) Day, Sandoz reaffirms its commitment to providing needed treatments for respiratory conditions such as COPD. COPD is a progressive disease that makes it hard to breathe, with symptoms that can affect aspects of everyday life<sup>1,2</sup>.</p><p>The most common symptoms of COPD include shortness of breath, abnormal sputum production, a chronic cough, wheezing and chest tightness4. Daily activities, such as walking up a short flight of stairs, can become very difficult as the condition ...</p> Nov 19, 2014 12226 Sandoz Inaugurates BioInject – a new state-of-the-art biopharmaceutical manufacturing facility in Schaftenau, Austria http://www.alloftv.com/news/media-releases/sandoz-inaugurates-bioinject-new-state-art-biopharmaceutical-manufacturing <ul><li>Sandoz is investing over 150 million euro and creating 100 new highly qualified jobs</li><li>The new BioInject facility will support Sandoz’s fast growing biosimilars business as well as other Novartis biologics</li><li>State-of-the-art technology will strengthen Sandoz and Novartis in-house capabilities in drug product manufacturing</li></ul><p><strong>Schaftenau, September 17 2015</strong>?– Sandoz, the generics and biosimilars business of Novartis, today officially opened its new cutting-edge biomanufacturing facility called BioInject, at Schaftenau in the Tyrolean Alps in Austria ...</p> Sep 17, 2015 12221 Global health challenges – including life expectancy – are influenced by gender http://www.alloftv.com/news/media-releases/global-health-challenges-including-life-expectancy-are-influenced-gender <p><strong>November 19, 2014</strong>?- The health challenges facing both men and women globally are heavily influenced by gender. Today, International Men’s Day, the global health community seeks to promote positive male role models, celebrate men’s positive contributions to society, focus on men’s health and wellbeing, highlight discrimination against males, and improve gender relations and promote gender equality.</p><p>Globally, men die younger than women. There are a number of reasons for this, such as biological, societal and behavioral differences.</p><p>Gender differences in health ...</p> Nov 19, 2014 12216 Sandoz opens office in Accra, Ghana http://www.alloftv.com/news/media-releases/sandoz-opens-office-accra-ghana <p style="list-style-type: none;"><strong style="list-style-type: none;">Holzkirchen, Germany, February 24, 2014 - </strong>Sandoz officially opened its representative office in Accra, Ghana on January 23, 2014.</p><p style="list-style-type: none;">The ceremony was attended by healthcare professionals including pharmacists, doctors, the Ghana health service, the Ministry of health, as well as Brigitte Cuendet, the Counsellor and Head of Economic Affairs at the Swiss Embassy in Ghana, and Edith Gavor, manager of the Ghana National Drug Programme (GNDP).</p><p style="list-style-type: none;">Ms ...</p> Feb 24, 2014 12211 US celebrates 30 years of rapid generics growth http://www.alloftv.com/news/media-releases/us-celebrates-30-years-rapid-generics-growth <p><strong>October 01, 2014?-</strong>?30 years ago, when President Ronald Reagan signed the legislation that would lay the basis for today’s US generics industry, even the law’s biggest fans never guessed quite how successful it would be.</p><p>One estimate - optimistic at the time - was that the new legislation, commonly known today as the Hatch Waxman Act, could save Americans a total of USD 1 billion.</p><p>A?<a href="http://www.alloftv.com/news/media-releases/generic-medicines-saved-us-healthcare-system-nearly-usd-240-billion-2013">study</a>?published this year by the IMS Institute for ...</p> Oct 01, 2014 12206 92午夜免费福利757-丝袜美腿